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I NTRODUOTION
I.

matorl!!:b note on ohollne.tex-.... '
Dale (21) aa .ax-17 as 1914 augg•• ted that an .nz,....

pHsent In the blood brought about the d•• tnotion of Ach.

(51) deaonatrated 1n 1926 the exi.tan•• ot

aD

Loew1

ODa,.. In extracts

prepared t.om heart muacle whiCh inacttvated a chollne •• ter
identtt1ed later .. Aoh. Bngelhart and. Laewi (29) In 1930
explalned. the

d.at~otlv• •etion

ot

t~.

blood Ach bJ 8uggesting

the exiatane. ot an e.tera.e wbich was compl.tolJ Inh1bited b7
minute amount.

ot phJaoatlgm1n.. About the s... time, the

oODd! tlona tor the lnaot! vation ot .lob were founcl to be conatstent
wi th the aotlon ot an •• terase.

Plattner and Buttner (11) were

the tirst to show in 19)0 that the en.,... i . present 1n near17
all anSmal tissue..

Stedman (76) proposed 1n 19.32 the name

cholinesteraso tor tho anzJme that h7dro1Jze. chollne eat.re.
II.

11.$&911;108

"tv«uta

tht \!O

me.

ot choMM!teEllt ,

owu

I

UDoez-tatntJ prevailed as to whether or Dot the h7dJtro1,.a1. ot Aoh waa oata17.ed b'1 a speclfio .n.,....

Stedman (76)

•••umed that 1RaD7 aeN oontalna two enzJ1D•• , at lo.at one b.lng
a lbE the other an ord1IU117 e.tera...

GllmaD and Goodmen (37)

flr.' apoke about apeolflc and non-speciflc ChE.
1

In a review b7

2

Augustineson (5), an ens.,.. which hydrolyzed only choline eaters
ia defined as a specifio abE.
exist in animal organisms.

Suoh an enzyme haa beeD proved to

!he physiologioal substrate 01' this

speoif10 enz1me 1s Ach.
The non-.pecif1c ebE 1s today def1ned as the enzJme which
can hydrolyze other e.ters in add1tioG to
latter being aplit at a higher rate.
at

O ..t:e

least~suoh

~olin.

eatera, the

Proof haa been o1'tered that

non·.pec1f10 CbE occurs 1n the antmal organiam.

However, the phys10logical function of this type 01' ChE 18 obscure
and the natural sUbatrate is not

wel1~

known.

Investigation of sensitivity to difterent 1nhibitors 01'
enz,.es trom various sourc.s oapable of splitting Aeh led Mendel
and Rudney (60) to propose a general classification 01' enzymes 01'
this type.

i'he term "true" or "spe01tic" CbE was reserved tor tke

enzyme. of erythrocyte. and nervous tissues_ which aoted O8ly on
choline eatera, ineludtng Ach, acetyl

~-methJlcholine

(Xecholyl)

but not bensoylohollne, and whioh were inhibited b,. high ooncentration of Aoh.

'1"h1. enzyme hydrolyze. choline eaters at a rate

inversely proportional to the length of the carbon ohain.

Certain

common eaters are split at rates which can be arranged 1n the
following order: but7l'7l (propionyl <aoetylcholine.

Bence the

name aoetylcholinestera.e (AcChE) was also given to the "true" CbB
On

the other hand, the term "pseudo" or non-specific CbE

included the enzymes fram serum, panoreas and other tissues whioh

3
hydrolyzed .loh, benzoylcholine and several non-choline eaters such
as tributyrin, trlproplonin and methylbutyrate but not Heoholyl.
'l'h1s enzyme exhibl ted maximum aoti vi ty in the presence of high
concentration of Ach.

The rat. ot hydrolysis by serum 0hE

increase. with the length ot the acyl Chain in the follOwing order
acetyl<propionyl<butyrylahollne, 1.e. in reverse order compared
to the sequence ot rates exhibited by AcChE.

Hence the name

butyrylchollnesterase (BuChE) was also given to this enzyme.
III.

Pez.iologiaa1 significance ot AaChE:
.loChE and its substrate

Ach~hold

an tmportant position

in the physiology ot the nervoua syste., while the importance of
BuChE is atill obscure.

The properties ot Ach ex.-ined by Dale

in 1914, who made the assumption that Ach is a synaptio neurohumor.

In 1921, Loewi waa the first to prove the exiatanae of a

humoral transmitter tor the parasy.mpathetic nervous system and
later postulated the hypothsis that paraayapathetio nerv.s aot by
liberating trom their terminals a chemical substan.e, asaumea to
be identical with Aoh, and in this wa,. tranami t the nerve impulae
to their ertector organa.

On the basis ot the exiatanc. in the

cella ot conducting tissues ot an enzyme with. relatively high
atfinity to .leh .aehmanahon and his coworkers (1939-1941)
hypotheai.ed

t~t

.loh baa a physiological role in O.N.S.

Kinetics

ot the aotivity ot .lcChE satisti.s the postulate that the electric
al activit1 ot the nervous system is initiated by the chemical
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action ot Ach at the aynapaea.
Altogether Naohmanahon as reoently as in 1960 held to a
"unitarian" hypothesis aocording to which ChE is a prerequisite
ofaxonal conduct1on as well as synaptic and neurohumoral transmission.

Generally however the synaptic and neurohumoral role of

CbE is more acceptable to most investigatores in this field.
Synaptio role ot CbE at the neuromyal junotion and in the C.N.S.
1s partioularly pertinent to the present researoh and will be
theretore described at some length.
1.

Neuromyal junction.

.~

Brown and Feldberg (12), Fatt and Katz ()O) and others
presented complete evidenoe for the ohemical transmission at the
end-plate region.

ebE alstem is aaid to be an integral part of

the meohanism responsible tor the development and propagation ot
action potential.

The looalization of the hldrolyzing enzlme has

been demonstrated bl histochemioal meana and ita local influence
on the transmission ot the impulse haa been elucidated by the us.

ot specific ChE inhibitors.

The enzyme action at the aeuromyal

junction eN.M.J.) does not oocur at other points ot the nervemuacle slstem.
The role of Acl;i. as a aynaptic transmitter and of CbB as
the other component of the cholinergic transmission system haa
been most studied at the N.M.J.

It was suggested (o.c.) on the

baail ot certain properties ot this synapse that its transmislion

S
system may have
C.N.S.

.1m1l.~ Impo~tance

at

othe~

sIte. such .s the

A. will b. seen from the next sectlon. evidence Is today

avaIlable indIcating that such may be the case.
2.

Cent~al ne~vou.

a.

0hE and

B~a1n

!he

p~e

en~e

cent~al t~an.mls.1on:

...ee of sueh transmission system 1n the C.N.S.

is possIble It the
brain.

sTstem.

componen~s

ot this system

a~e

present in the

The components .~e the chemical transmitter (Ach), an

to synthesize the transmitter (chollne acetylase) and an

enzyme to hydrolyze the transmi tte~ (loChE).
1.

Ach has been tound in the

which could be

oo~related

b~ain

in a concentratIon

with tha activIty ot the C.N.S.

Gene~al-

11 no other choline e.ters have been shown to be present In the

braIn.
11.
and its

p~esenoe

ot Ach in the
high

Choline acetyla.e (31) has been found in the braIn
could be

b~a1n.

concent~atlon

co~elated

to an extent with the presene

Ach and cholIne aoetylase have been found in

In the cerebellum and In the Htlcular

fo~atlon.

111.

Both AoObE and BuChE have been found In the

AcChB predominates In the gray matter.

b~aln.

It has now been establish-

ed that the ensJae in all nerve tIssues Is eIther exclusIvely or
predOminantly speoltio tor Ach.

The localIzation ot AcChE i.

cos-related with that of Ach In the brain: both are found In high
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concentration in the cerebellum and the reticular tor.matlan.
The CbE act1vity 1s correlated with neurogenesis and ontogenic
development ot brain !unction, 1ncluding ontogenic emergenoe or
electrical actIvIt7 ot the cortex (32).

S1m1lar correlat10n was

made with regard to choline acetylase.
b.

8Rinal cord:
Evidence exist. which indicates that at least 80me ot the

important synaps.s 1n the spinal oord such as the synapse between
the collateral and the Renshaw cell are oholinergic.
cella (72) are looated in the

ventral~root

The Renshaw

of the sp1nal oord.

Recurrent oollatera1s ot the motoneuron impinge on the Renshaw
cells.

It ha. been proposed by Eccle. et al (28) that the Renshaw

cell is an interneuron which ean be tired b'y antidromic stim:u1atlo
ion of the motor nerves and which is capable ot evoking a wave ot
hyperpolarization in the motoneuron.

The

ph8~aoo1ogical

charact-

erisatIon or the synapse between the recurrent col1aterals ot the
motoneuron and the Renshaw cell Indicates that this is a oholinergic synapse (27,28).

Lengo et 81 (S8) inve.tigated

~.

ettect.

of physostigmine and dlhydro (j-el7thro1d1ne on the trequency ot
spike activit7 ot the Renshaw cell.
~-erythroid1ne

!hey tound that dlhJd:ro-

decreased the frequency of the burs;

during the first tive msec.

D1hJdro.~-erythr01dine

ed the duratIon ot the Renshaw burst (Bccles,26).

of

the cell

also attenuat-

In agreement

with Ecoles (27,28) Longo tound that physostigmine prolonged the
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duration of the
measur~ent8

d1scha~ge

of the Renshaw cell

bu~st.

However

ot the relationship between the time course ot the

Benshaw cell burst and stimulus strength yielded data inconsistent
with the hypothesis that the dutation of the burst is determined

The etfect of

solely by the rate ot the hydrolysis ot Ach.

physostigmine in prolonging the Renshaw cell burst can be explained on the basis that, in the

p~esence

of a reduced concentration

of effective esterase, the rate of hydrolysis

at a slower

~ate

o~

Ach would proceed

and the concentration of Ach available for

oombinations with effector reoeptors ·would. be increased.

Ach

would cause then membraIllt change per8isting beyond the time of
its physioal presenoe.
o.

Other 8ites in the Central nervous system:
Other sltes in the C.B.S. may be oholinergic as implied

by certain pharmacological investigations.

Karcamar and Long (49)

have studied antagoniSM of the toxici t1 ot an anticholinesterase
(TEPP) by atropin8 .ubstitutes, and sugg.sted that both TEPP
toxicity and protection against TEPP are central in nature.

!hey

have found that the structural changes in the atropine substItutes
that increaae the peripheral cholinolytic potency also lncrease
the anti-TEPP action supplying therefore evid.ence for the hypothesis that cholinergio transmission is involved in the central
action of TEPP and in its antagonisM by atropine-like compounds.
Other pharmaoologioal evidenoe tor chol1nergic transmiss-

8
It was shown for instance

ion in the C.N.S. was also obtained.

hat "hemioholiniums" whioh are thought to blook the formation of
Aoh by blocking the transfer of choline to the site of the reaotion, posses a highly toxic action against respiration via a
oentral meohanism, probably within the relay oentera tor respiration ot the spinal cord (75).

Otner evidenoe for oholinergio

transmission in the cortex has shown that when Aoh is given I.A.
or added looally to the cortex it increased the

si~e

of the

spontaneous bursts of EEG, produced tremors and even oonvulsions.
This indioates facilitation of oholinergic transmission at
"

oortioal synapse (tor references cf. 53), Koppanyi (53) suggested
theretore that Ach affects oholinergic electrical activity of the
cortex.

Hypothalamic and reticular transmission may be also

oholinergic.

D-tuboourarine, a cholinergic blocking agent at the

N.M.J., blocks upon intra-ventrioular injeotion the effeots of
hypothalamio stimUlation on oardiao contraotility and acoeleration
(Paiss, 70).

Bradley (10) has shown that cholinergio oompounds

suoh as DFP, can alert the mid brain and reticular formation,
probably at the thalamio level.
d.

Physiological significance of other ChEs:
While no other esters of choline except Aoh were gener

ally found in the C.N.S., this is not neoessarily true elsewhere.
Romologues ot Aoh such as Proh have been demonstrated in ox spleen

(9).

BuChE has reoently been demonstrated to be present in the

9
motor end-plate
este~s

~egion

(44).

as well as of BuChE or

The physiological role of these
~elated

suggested by Whittaker (78) and

ChE i8 not known.

Karczm~

It was

et ale (50) that the

physiological role of BuChE might be to hydrolyze particularly in
blood choline esters other than Ach, which may appear there as
undesirable metabolites.

BuChE may be also involved in intestinal

motility and contractility (52).

The physiological role of Prch

is still obscure.
IV.

Determination of CnE activity:
1.

Methods of determination:
More than one method has been used to determine CnE

activity.
a.

Biological methods, in which Ach concentration was

bioassayed on smooth muscle or on cat blood pressure betore and
atter exposing the Ach solution to samples of biological material
containing CnE.
b.

Chemical methods, in which the acetic acid liberated

from hydrolysis ot Ach is determined'
A.

By titrating with an alkaline solution of known

concentration using an indicator or by electrometric titration.
B.

Manometric methods:
i.

Warburg method is most oonvenient for follow-

ing the time course of hydrolysis of Ach, it is also most suitable
for use in comparative and serial experiments.

Ammon (3) was

first to use thia

me~hod

in assaying CbE activity.
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In thil method

C02 is liberated from buffered bioarbonate system by aoetic acid
formed during Acn hydrolysis by CnE ot the sample, C02 il then
measured manometrically.
ii.

Van Slyke method is based on the same princip

le as that of Warburg and employs different apparatus.
iii.

Microchemioal gasometric method has been

sucdessfully applied to the study of the ChE activity by
Linderstrom-Lang et ale (56).

The principle of the Cartesian

diver is applied in this method.
C.

..

.

A photometric method is based on the ferric chlo

ride reaction with acetic acid liberated by CbE trom the substrate
D.

A histoohemioal method was first used by Koelle

(51) and moditied by Holmstedt (45) and others.

The method

depends upon complex tormation by Ach thio-derivatives and cupric
ion.

By treatment with ammonium sulfide this oomplex changes to a

black precipitate of euS which localizes the enzyme microscopically.

In this method thio-derivatives ot Ach and Buch are used as

substrate. for determination of true and pseudo ChE respectively,
differential inhibitor. are used additionally.
2.

Units used in 8!2ressing CnE activitl=
a.

Naonmansohnta Q and A values are defined as follows:

Q, mg Ach hydrolyzed in 60 minutes by 100 mg tissue at 20° C

A. mg Ach hydrolyzed
b.

in 60 minutes by 1 mg protein

Some investigators express enzyme aotivity in pl of
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C02 evolved in 15 or 60 minutes by the sample.

Figures for

evolution ot CO 2 can be used to calculate the amount of Ach
hydrolyzed: 1 p.l CO 2 = 8.1 Ilg Ach or 1 mg Ach = 123.5 pl C02
Augustinsson's ct and b30 values are defined as folCf= Aoh pmole destroyed/60 minutes/mg dry substanoe.
c.

lows:
b 30

= CO 2 pl/30 minutes.
3.

Faotors affecting the determination ot CnE activitlt
a.

Etfect of H ions concentration) at pH 2 the non-

specific ChE is oompletely destroyed; it starts to deoline in the
alkaline range.

Its optimum pH is 8 to 8.5.

speoifio ChE is 7.5 to 8 (4).
ed.

Optimum pH for

.~

At pH 4.5 it is oompletely destroy

The stability in alkaline reactions of AoChE also seems to

be less than that of BuChE.
b.

Optimum temperature tor both AoChE and BuChE is 37

o

to 40 0 C (38).
o.

t+

Aotivators are said to be Ca

+~

,Mg

~~

, Mn

and some

organic compounds (67).
-tt'

Inhibitors are said to be Cu

v.

++

and Co

(2, 67).

Warburg method:
1.

The Warburg apparatus:
Conioal flasks (15-20 ml volume) are used.

Warburg mano-

meters are tilled up with Brodie solution (23 gm Nacl + 5 gm
Na choleate in 500 ml water).

Evan's blue dye is used in a

solution having a density of 1.034, so that a 10,000 mm level
difterence

of Brodie

solution~760

rom Hg.

Contents ot flasks

u
are mixed by means ot .baking motor.

•

The flasks are connected to

the manometers and are placed ln a water bath the

tempera~.

of

which is constant and thermo regulated.
2.

The theorI ot the manometrlc technique:

The condition. ot the •• say must be auch that in a reaction
medium a certain gas ls elther eYOlved traa Or absorbed by the
reaction

~tur..

At constant volume the gaa pressure can be

recorded trom the change. ln the level ot manometer tluid.

In th

case of ChE, the sub.trat.s suGh as Ach or Blch are h7droly.ed by
the enzyme..
benzoic acld.

The product. of

h7drol~is

are chollne + a.etic or

The acid i. then reacted with the bicarbonate and

the resulting CO2 gas ls evolved. Its pre.sure is a measure ot
the activity of the abE present in the reacting medlum. The
chemical reactlons which ocaur are as tollows:
1.

AcChE+ Ol(OB,),N-Ci2-0B2-0-CO-CH, ~ AcOhE + choline +
acetic aoid

ii. CH,-COOK + B&HCO,

---t

CH,-OOONa +

120 +

CO2

A thermobaroaeter tlask which contains 3 ml ot water and a control
tla.k containing bioarbonate solution and sUbstrate solutioD ot
the .ame concentrations as that added to the brain homogenates,
are included in all experiments.

Correctlons tor thermobaroaeter

changes (due to alterations in temperature and pressure) and tor
the non-enzy.m!c hydro11sis ot the substrate are made.
!h. absolute volume ot CO2 liberated by the enaym10 hydrolys1s ot the substrate / unit time / mg brain tissue, can be
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oalculated.

In the cas. ot analysing brain tissue treated with

lnhibitors, the percent of remaining ebE aotivity and ot ChE
lnh1bi tion oan be caloulated provided control values are known.
VI.

Inh1bl topa ot ObE_
1. !be ors&nophoaphorus

anticholin.at.rase~t

The anticholinesterase agenta constitute one ot the tew
classes of druge tor whioh a mechani.- ot action has been defined
ln ter.ms ot inhibItion ot a apecific en.,...
Priop to War I, Dixon and Ransom and Fras.r desoribed
phar.macologioal aotions ot physoatigmine and demonstrated
physostigmine mioais and slOwing up ot the heart as earl,. a.
betore the turn ot the centu17.
naturall,. did not

mow

At that t1me the.e investigators

that this substance is an anticholine.ter-

.. e or, in tact, that th1. mechanism ot aotion exists and the,.
described actions of ph,.sostigm1ne a. muscarinic or stimulant to
the parasympathetic syat...
The mechanism ot action ot physostigmine was studied atter
the role ot abE was eluoidated aa alre.d7 described.

Streus and

Goldstein (1943) showed that pbJaostigm1ne and Aoh enter into a
competition tor the aotive ait•• on the surtace ot the eDSJ.m8.
Displacement ot Aoh by pbJaoatigm1ne nulllties the capaci t.,. ot
the ens,me to hydrolyse Ach.
Another important development was the demonstration ot
anti-curare actlon ot physostigmine (Walker).

The clinical

~

similarity between the loss ot skeletal muscle tone in myasthenia
gravis and in curare poisoning led Mary Walker to conceive the
idea that physostigmine which evoked a decurarizing action might
be useful in the treatment of the disease.

In 1934 she treated

her first patient suffering trom myasthenia with physostigmine
salicylate and observed dramatic improvement.
Prior to War II, CbE was not ot wide interest; the advent

ot the organophosphorus anti-cholinesterase agents at about the
time ot War II which was due to Schrader's synthesis ot some ot
these compounds brought new aspects to this area and CbE
determination have become of practical importance in industrial
health, crop protection and study ot insecticides, and in work
on chemical wartare.

The new agents served as antimyasthenics

(TEPP, OMPA), or as war gases which .ere tirst synthesized in
Germany and in England where Saunders prepared alkylphosphoryl
tluoride (DFP), or tinally as insecticides (Parathion, EPN and
Malathion).

The last two compounds are the compounds used in the

present study and they will be described later in some detail
with respect to their chemistry, biochemistry and pharmacology.
2.

Stereospeciticitz ot organophosphorus anticholinesterases!
The ObE inhibitors ot organophosphorus group can be given

the general tormula proposed as early as in 1937 by Schrader, tor
derivatives ot phosphorus acid with insecticidal properties (Fig.
la).

Biologically active compounds are obtained when in addition
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to oxygen or sulfur, two similar or dissimilar substitients are
bound to the phosphorus atom and an organic or inorganic acid
residue is also present.

Rl and R2 are oapable of almost infinit

variation.
The stereochemistry ot the anticholinesterases of the
phosphorus group has been very little inVestigated although it is
well recognized that enzrmes exhibit stereospecificity.

Such

specificity is likely to be the consequence of the asymmetric
structure of the enzyme surtace.
morpha of an asymmetric orgaaic
synthesized (1).

Recently the d- and 1- enantlophos~orus

inhibitor of CaE were

It was found that the 1- isomer inactivated

irreversibly four ChE preparations from 10 to 20 times taster
than the d- form (1).

3.

Inhibition of ChE bl organophosphorus compounds:
Wilson (77) has suggested a basic similarity between the

interaction of Ach on one hand and of organophosphorus compounds
on the other with ChE, despite the faot that the carboxyl esters
suoh

aa

Ach are usually substrates and the phosphoryl derivatives

are inhibitors of ChE.

The foroes between Aoh and the enzrme

are thought to be of three kinds at least (66),
a.

Ionio bond: The active surface of the enzrme protein

contains a negatively charged site, the "anionic site" (77), whic
reacts by cOQlombic forces with the positive eleotrio oharge of
Ach (the cationic nitrogen), and contributes hereby to the
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attraction, fixation and orientation of the substrate upon the
enzyme surface.
b.

Covalent bond: There is also another group at the enzyme

surface which reacts with the ester group of !ch by a covalent
bond; this grouping has been referred to a8 the esteratic site.
c.

Van der Waals attraction between the substrate Ach and

the enzyme.
The suggested similarity between the affinity of organophosphorus compounds and of Ach to the enzyme (13) can be
.,

demonstrated as follows:

H-G
i.

ff-G

+ CH)-COOR

(enzyme)

ii. R-G

+

G

l

>

<

l\

R-O-C-O

~

I
OR

(Ach)

I

+

ROH

OR)

3

0
II

0-0

G

II

(RO) 2P.iwF

~

p-O

/\

+

HP

RO OR

(dialkJl phosphoryl enzyme)
The bonding between Ach and the enzyme is easily broken down by
hydrolysis.

A. tar

a8

the interaction between the enzyme and

the inhibitor is concerned, labeling ot the organophosphorus

32

inhibitors with P

and the inhibitor is

has shown that the bond between the enzyme
80

strong that it is not broken down by

dialysis or by recr:fa t alization of the enzyme (16).

In the

inhibitor-enzyme complex the phosphorus atom represents a strong
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A,

SCHRADER~ FOftMULA

EMZYNE SU"FACr

8.

PHOSPHO~ATE

ACTIVATOR

FlooRE 1
A.

B.

GENERAL FORMULA FOR ORGANOPHOSPROEIJS OOMPOOIDS

REACTIVATION OF

cum,

INHIBITED BY ORGANO-

PHOSPHORUS OOMPOtnm. BY iir;

CX~hE

AGENT.
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electrophilic center • This is a positive center whicn i.
attracted to a negatively charged center at the enzrme surtace
and theretore doe. not react with water to regenerate the active
enzyme as readily as Ach-enzrme complex.
It is possible however to regenerate the active enzyme by
using nucleophilic reagents which are attracted to a positively
charged center i.e. P atom ot the inhibitor.

A large number of

reactivators were studied, such aa hydroxylamine, pyridine and
hydroxamic aoid methiodide (17).

Reactivation occurs when

because of coulombic attraction the reactivat&r can attack the
phosphoryl group of the inhibited enzyme (Fig. lb). Hydrolysis
of the phosphoryl group is ba.ed on the same principle aa Ach
in the ca.e of Ach-enzyme com,lax.

hydro~y.is

i.

H

H-6 +
ii.

f +

H-O

?'~_

~

f-O
OR)

L~

'"

>

,,-0

BO OR

H-Gf

1\-0

+

OR

<~ I~

)
H-G
'T +
+
(r.activat7RO OR
HO OR
or
The organophosphorus anticholinesterase. that form comlexe. with

the enzyme which are not easily hydrolyzed such as DFP, are cal
"irreversible" inhibitor..

W.en given in vivo they

~roduee
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inhibition such that the enzyme activity cannot be restored until
new enzyme is synthesized.

Other ObE inhibitors form ea8ily

hydrolyzable complexes with the enzyme and therefore are called
"reversible" inhIbitors, such a8 physostigmine.

Toxicity caused

by a reversible ChE inhibitor is temporary and normal activity of
the enzyme is rapidly restored by its liberation from its complex
with the inhibitor.

4.

Toxicitl of organophosphorus anticholinesterases:
DFP as an example ot tl:1is group or agents produoes the

following general effects (64): Motor!unrest, muscle twitching,
tremors, ataxia, weakness, respiratory stimulation, salivation,
miosi., bradycardia, defecation, diarrhea, and finally oonvulsions which lead to respiratory depression and death.
These symptoms fall into two groups: a) peripheral effects
due to muscarinic stimUlation of respiratory and gastrointestinal tracts, and to nicotinic action on skeletal, particularly
respiratory muscles, and, b) central effects.
The meohanism inducing this toxic picture undoubtedly
involves ChE inhibition.

This in turn leads to Ach accumUlation

which again probably oocurs both centrally and at the periphery.
A direct toxio effect on the C.N.S. is considered of
primary importance in CnE poisoning (23) and may be demonstrated
by the following data:
a.

Michaelis et al.(63) demonstrated that a phosphonate

20
anticholinesterase causes central accumulation ot Ach.
b.

Karczmar and Long (48) showed that the mechanism involv-

ed in the protective action against TEPP toxicity of atropine
and its congeners is both central and cholinergic in nature, sinct
their protection against central toxicity parallels that against
peripheral toxicity.
c.

Analysis of AcChE activitJ of pons and medulla follo'Vling

TEPP administration indicated that following marked initial
potentiation of respiratory retlex which was maximal a·t 10 to 12
peroent inhibition of AcChE there

wa~

a gradual but progressive

deoline in the potentiated respiratory reflex in parallel with
the tall of AcChE activity of regions vitally concerBed with
respiration until respiratory failure was evident at 89 to 92
peroent inhibition levels.

The experiments suggested that the

cholinergic transmitter Aoh, may be a factor in respiratpry
control (62)
d.

As tar as the electrioal activity of the cortex i8

conoerned the errects of organophospho.us compounds comprise EEG
d •• ynohronization, convulsions and tloal11 quiescence.

The

convulsions may ultimately block respiratory activity which will
have already been reduoed by muscarinic actions on the respiratory tract and by the depressant effect of anticholinesteraso
compounds on the respiratory centers and muscles.

The de-

synchronization of EEG 1s the first Sign of action of the

anti~

2l
ohol1nesteraae ooapounda on the aaoend1ng retloul.ar aotlva\1Dg

81.t-

O~

MONaal and MaDgun.

Reoent studies bl Bradle,. (11) an4

1:I1mw1oh (4J.) lnd10ate that chollnerglc drugs 40 not appe&J' to aot

only on a meoban1am oont1"0111ng KEG pattern but 81ao em another

meohan1am wb10h ls not oOlloerae4 with behavioural ohanges nob

aa waketulneaa and al•• p.

e.
o~

It baa been lIentloned el.l'11 •• that reouITeDt ool1atel'ala

the motoneuron and the Renahaw oell conat1 tute. a ohoUne.-g1.o

ajn&pa••
OIl the other harl4. there

aH

'ltome data which 1D41.oate

that tox101't7 -7 not alva,.a depend e1ther oa g.neMl

1nh1b1tlOD

o~ abE.

01'

oentral

Frawley at al. (33) ha.a show that DFP

&Xh1b1ted miniJD'lllD .,..ptoma when bra1n abE wu 1nh1blted by 92
peNent,
the aotl vi

on the other band, Parath.Lon and TEPP Nduoed

t,.

to 20 pel'Cent and S1 percent ot normal N.peOtl.al,.,

conoomltant17 with a.vere aJlllptoaa.

They oonolud.4 that vh11.

brain abE 1nh1bl tlon _,. OODtl'1 but. to the alJllPt0a8 obael"nd.

1t 1. not alva78 the ma1n cau•• ot death 1n the
ph08phonate tox101t,..

0 . . . o~

'l'.be •• data nsse.t that at oonwlal••

do ••• central abE lDh1blt1on 18 not equal w1 th the•• two
oompounds,

tbua, either oonw1alone are central but not clu. to

central abE lnh1bltlon, or pel'1pheral and 100all •• d at N.M.l.
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An important oonsideration il whioh part ot the brain was analyzed tor the ChE activity.

Small inhibition at one particular lite

does not necessarily mean that equally Imall inhibition ocoured
The data ot Frawley et al are also in disagreement

at all sit.s.

with the results or Metz (62) showing that respiratory tailure
with TEPP was evident at 90 percent inhibition ot medullary AcChE
and with the results ot Karczmar and Long (48) whioh were already
desoribed.

5.

Brain Barrier and orSanophosphorus antioholine.terase.:
It has been known long that sOme compounds penetrate more

easily than other blood brain barrier.

This i8 true tor example

ot tertiaries which can croas the barrier more readily than the
quaternary amines.
solubility.

This has been related to dirterenoe. in lipoi

It haa also been known long that cer'ain substanoes

cause central ettects and at the .ame time damage blood brain
barrier to such an extent that the damage can be visualized with
vital .taining by trypan blue.
central etteots
barrier (68).

with~ut

Tertiary OhE inhibitors produce

destroying to any extent the blood brain

The penetrability ot sultanilamide, ,_hieh i_

measured by calculating the ratio ot this substance that pen.-rat
into the brain to that in plasma, into the brain wal found to
inorease with inorea.ing permeability of blood brain barrier.
Paulet and Andre (69) used this teat to investigate the relationship between the anticholine.teraaic ertect and the ohange in
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permeability ot blood brain barrier of some organophosphonate
oompounds.

Tney tound that some antioholinesterases suen aa

Parathion and OMPA increased tne permeability of blood brain
barrier, and that tni. property appeared to be independent trom
the antioholineateraaic activity ot tnose sUbatanoes.
6.

Metabolisll ot the organophosl2horus antioholineaterases:
In 19S0, Duboia (24) and Gardiner (36) reported metabolic

oonversion of organophosphorus oompounds to antioholineaterase
agenta.

Casida (16) and Cage (1$) have shown that many organo-

phoaphate esters are toxic in vivo and yet ineffioient as ChE
inhibitors in vitro; thus theIr metabolio oonversion to more
aotive anticholineaterasea can be auspected.

Metcalf and Maroh

(61) used the Warbure teohnique to determine the activity or EPN
and Malathion incubated with liver slioe..

House fly head

enzyme was aensitive to those oompounda after incubation.

Para-

thion metaboliam naB been ahown to result in an isomerization
between the thiono-sulfur and tbe ethoxy-oxygen, rendering it a
more potent antioholinesterase.

Thus, metabolism in vivo,

catalyzed frequently by liver enzymes may lead to tormation ot
more toxic oompounda.

Th. opposite oan ooour also, and is a

major oonsideration in the evaluation of modern inseoticides.
Malathion,an insectioide of extreme importanoe at present, has
tne advantage or being mucn less toxic to mammals tnan to insects
beeaus. it is broken down in vivo to inaotive compounds a8 snown

24in the hen, mouse and

~oach

(59).

In

vit~o

studies by Cook et a1

(18) showed that Malathion is altered very quickly by

~at 11ve~

when it is hydrolyzed at the diethyl succinate group to a compoun
which is inetrective and

mo~e

water soluble.

This breakdown or

Malathion may be inhibited by certain organophosphorus compounds.
It has been shown by Murphy and Dubois (65) and by Cook (19)
that EPN as well as some - but not all - other
compounds inhibit Mala_hion-detoxitting

live~

o~ganophoaphorus

enzyme.

The

or EPM inhibited liver enzyme oocurs in a matter ot a

~.oove~y

rew days.

This point or great

perti~enoe

to the present researeh

will be discussed in greater detail subsequently.

7.

Biochemical and pharmacological action. or EPN and
Malathiom:

.m wu

synthesized during the war and shown to be an

insecticide belonging to the general class ot compounds referred
to a. organophosphorus insecticides.

Chemically it il O-ethyl-

O-P-nitrophenyl thionobenzene pho.phonate (Fig. 2).

The technica

EPN 1s a dark amber liquid, soluble in most ot the oommon

o~ganic

solvents and stable at ordinary temprature.
EPN produced

ma~ked

inhibition ot human erythrocyte. CnE

slowly increasing with tim. (42); deoreale ot ChE activit7 to
53 percent or initial activity occured in 200 to 300 minutes.
CbE inhibition by EjN i8

irreve~.ible

inhibitory action in vitro.

(42).

EPM lacks high CbE

In vivo, the intoxication i8 cholin-

t'I~

~I
~

);- -s
b
f~
CHI
EPN

MALATHION

PIWRB 2
STRO CTURAL PORMULAE FOR EPN AND MALATHION
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ergic in nature and exhibits C.N.S. manifestations.

In general,

intoxication symptoms are those characteristic ot anticholinesterale agents.

EPN is considered as one ot the potent toxic

organophosphorus compounds and its LDSO in dogs is 20 to 30
mg / Kg orally.
Malathion is chemically O,O-dimethyl S-(1,2-dicarbethoxy)
ethyl dithiophosphonate (Fig. 2).
(14).

It was Iynthesized by Casaday

r1alathion is a yellowish oily liquid, having a strong

smell ot garlic, slif{htly soluble in water, miscible in most
commonly employed organ1c solvents

an4 stable at ordinary

temperatue and pressure.
The pharmacological action ot Malath10n seema med1ated by
the inhibit10n or tissue enE; the ligns ot toxicity atter a large
single dose in experimental animals are almost exclusively
characteristic of oholinergic intoxication.

Among those are

excessive lalivation, depression, tremors, convuls1ons, coma
and death.

Its inhib1tion ot ObE is irreversible (40).

It baa

a relatively low mammalian toxicity with an exceptionally wide
range ot activity against insects.

It is one ot the tew organic

phoaphonate insectioides that 1s considered aate enough to
justify availability in commerce tor general insect oontrol uae,
It is weak anticholinesterase when compared with Parathion and
EPN.

It wal stated that in dogs, Malathion given I.V. inhibited

plasma ChE more than RBG and brain CbE (40), while Parathion and
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EPN inhibited more RBC and brain CbE.

It was also said that an

ettective dose of l'1alathion increased blood pressure (40) followed by respiratory failure, Metrazol and artificial respiration
failed to revive the animals.

8.

~ot.ntl.tion

bl oombination of ori&nophosphorua anti-

ohol:lnestex-uu:
The possibility exiata that a worker may be exposed to
two or more insecticides on tue same or difterent day., and that
intoxication may aooidentally ocour by ingesting several difteren
."

food products, eaoh containing a difterent insecticide.
prompted

F'rawl~y

Thia

et al (34,3$) in 1957, to oarry out a aerie. ot

experimenta on the additive aotion ot EPN and Malathion.

The

data ahowed potentiation of aoute toxioit1 ot EPN and Malathion
when they were administered simultaneously to dogs.
iation was leaa marked in rata.
RBC CbE was noticed also.

Potent-

Potentiation ot inhibition ot

Frawley et ale auggested that the

meohanisM ot potentiation ia not a chemical reaction between the
two phosphonates, but that the potentiation ot ebE inhib1t1on 1n
RBC 18 a results ot a prior reaotion ot one or both ot tb.e
compounds with another biologioal system.

Sinoe it waa

ed that phosphonates are enzymatioally detoxified and

demonstr~

t~at

this

can be blocked by oertain other pnospbonates, Oook et ale (19)
sugge.ted that this is tne baais ot the potentiation ot Halataion
by EPN.

Rosenberg (73) confirmed tb.at EPN potentiate tox1.oit1
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ot r!alath!on when th.. two oompounds ares! yen orally simultaneous 1y

;0 l"ats. TIe showed also

that combinations of Malatblon

with ONPA, Parathion, DPP or with physostlgmine show minImal
Combinations ot EPN-Faratnion,

no potentiation.

E:)l~-Oi"iPA

O!'1PA.Paratb.lon exhibIted no potentIation of toxicity (7.3.

01"

and
7L~).

Beaidea potentIation ot CUE Ulhlbltion, pharmaoological potentiation at epelfic neuroetteotors, such. &8 vagal, ganglionic,
neuromyal and at tn. C.N.S. w•• also dem6nstrated (39).
Howev.~

botn potentiation of enzymio inhibition and of
.~

neuroettectoll toxioity need not be entirely due to ttle meohanism
IUgs •• tedof Cook et a1. (19) alnee it was snown earlier tilat

even

quatern~7

compounds which should not be hydl"olyzed by tne

.nape. desoribed by Cook (19) also potentiate eaoh othel' (Lands,
Hoppe, Kareamu and Arnold~ $$).

led to tne pre••nt

r.ae~oh

TtUa 18 one

ot the points tnat

and w111 be discussed mOl'e 1n detail

in tn8 next aeetion.
VII.

Tg8 isrR2!.

2' tn! weist atuS,.

A jerie. o£ ayntuetio organopi:loapno1"Us compounds, b•• ides
being employed as pnarmacologioal tools, are used as cno1lnerglc
agents In therapy and as inseoticidel.

Ta.1I' applioation in

agriculture Is oontinuously expanding.

Many que.tions regarding

their pharmacologioal act10n must be Answered, for the protection

ot the manu,tacturer as well .s tn.e consumer ot

tn.

treated rood.

ChE 1nvestigations were d.ai3ned to evaluate the relationship

or

~

inhibition to symptomatology_
laboratories and from

A

Fede~al

certain anticholineaterase

~ecent

demonstration trom

ou~

Food and Drug Administration that

W~

gases and inaecticides potentiate

the toxioity of eaoh other rather than act merely addltlYely Is
to be conaidered in view of the possibility of aimultaneoul
expoaure to two or
p~ofound

mo~e

ot theae compounds.

This phenomenon has

theoretioal and practioal implications and points out

the need for oaution in the

USE

of drug oombinations in the field

or therapeutios and tor additional investigations in this frequently overlooked phase ot

pharmaco~ogy

and toxioology, parti.

cularly since organophosphoru.s oompounds ot particular interest
in the present study, EPN and

~alathion,

are among taose which

are in greatest use in agriculture.

The potentiation was however inadequately studied.
There was no previous 8ystematic investigation ot these two
compounds as to the dose-effect

~elationship

ot the1r antioholin-

eateras. act1on, the type of tbe1r interaction with the enzyme
or to the relationship between the extent of inhibition partioularly at strategio er£ector sites. and toxioity.

Potentiation

ot CbE inhibit10n waS generally demonstrated with reterenoe to
blood

enz~ne8,

and not enQugh data are available as to 0hE

r •• ponse of other tissues, particularly of the G.N.S.

Per ae

potentiation ot inhibition ot the blood enzyme cannot account
tor the rapid death observed, although it is generally thou§;ht
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that tne inhIbition of this enzrme il

~eaponslble to~

the action

ot the individual compounds and a180 tor the potentiation ot the
toxioity ariSing trom the admini.tration of their combination ••
Finally, inbibltlon ot detoxification ot one compound by
by the otner

Wal

the eXplanation ottered tor tile potentiation of

the .n&1II1c inhibition and of tonolty ari8ing; from oomblned
acJmlnlltration ot tne•• compounds.

This explanation naturally

do•• away with the difficulty of underatandin6 the mechanism
whep.by en_lvally slml1a1' compound. whicb. snould react with
identical radioals ot the enzyme

act·~m!l>re

tllan addltivel,..

11ow-

evel", indication. tllat anothernlS'chanisr.1l-ms 'involved were'
alpeady mentioned.
The abo•• qu •• tions nece•• ltate a detailed study of interaction. between EPN, Malathion and the enzyme in vivo and in
v1tpo wIth l'eg&1'd to potentiation of Inhibition ot

a.M.S. enzyme,

dependenoe ot inhibition on EPN and Malatb.ion metabollam, and
type ot !PH and Malataion lntaractlon with the onE. It Val a180

nec •• eary to reexamine tbe h1Potb•• la ot COok, and to att"pt
it

n.a.8.~1

atlon.
ate

.u~g.at

\'lilile

F1nally,~tne

pre.en~

mi •• ion

to

'it

alternatlYe ••enanism.

to~

the potent1.

pre.ent re••arch i . not conceived to elucid-

,unoertalnlt,. ot tne mechanism ot oent!'al t1-ana.
mtlJ ,.ield additional olue. for tne understanding

ot the tunction ot ChE in the O.H.!.

CHAPTER II
PROCEDURES

I.

Technical -PEroacn to tn. Ere.ent studl:
The two compounds in question, EPN and Malatbion, were

given singly and in combination and studied in vitro as well as
in vivol Warburg manometric technique was ueed for tne measurement of abE activity.

In vivo studies were carried out b,.

injecting the compounds into tne temoral vein of anesthetized
animals and intraJugularl,. and intraventricularl,. to tne "upper
animal".

The "upper animal" (ct. intra) technique was used to

suppll intormation .s to whether or not tne metabolism of these
compounds is necessarl tor their actions.
The in vitro stUdies were carried out by adding compounds
to brain homogenates.

In other instances thel were incubated

with. liver, then added to brain homogenate.

The in vitro studi.is

had as their purpo.e first, to inv •• tigate the conditions in
which. the potentiation mayor may not occur, particulatly with
regard to the necessi.tl ot liTer incubation tor pot.entiation.
Secondly, it vaa ascertained whether or not the enzJMic inhibition bl compounds in question was irreversible aa suggested bl
Hazleton et al. (40) and thia was tested bl dialysis and dilution
technique..

ae.ides theoretical implications ot tb.1s the
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irrevelibility or their action renders the measurments or

inhibi~

ion ocouring in vivo more reliable, ainoe it precludes reveraibility of inhibition during meaaurments.
II.

Preparation of the animal (general):
Doga were uled for the present study.

They were anes-

thetized with an average dose of 30 mg/Kg of Na pentobarbltal,
given I.P.

The average weight of the animals was 8 Kg.

The

femoral vein was expo.ed for I.V. injeotion of the compounds In
question.

At a certain time atter the injection, the animals

were lacritied by dividing the spinal cord at a level below the
medulla.

Tbe lkull wal opened and tbe brain wal taken out foro

biochemical analYlis.

In lome instances, the brain lamples were

kept in the rerriseratoro and were analy.ed tbe followlng day.
III.

PreparatIon gt 'be "uppe. anImal".
This Ipecial anImal proeparation wal done ror the purpole

ot studying the etfect of tbe compounds 1ft question without
compounds being ciroulated through tbe liver or any other vilcera
organs.

The dogs were aneithetized al mentioned above, the

trachea wal expo.ed and a tracheal oannula was inlerted tor
arotiticial re.piration.

Tbe aorta va. 11gated above the level

of the hepatic artery.

Thil W.I done by making a Imall inci810n

in the diaphragmatic membrane through which a ligature was
clamped on the aorta.

To reaoh the diaphragm, an Inci.ion was

made in the abdomen, then the me. enteric viaceral membrane was

separatea from the abdominal wall.
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In this way, hemorrage and

blood loss was avoided to a great exyent.

Subsequently, the

animal va. kept under artifioial respiration during the remainder
of the experiment.

At the end of most experiments the state of

aortic ligature was ohecked to asoertain the success of this
form of hepateotomy.

Additional indioation of the sucoesa ot

the procedure was that the blood vessels of the liver were always
noticed to be collapsed.
The drug. were administered to the "upper animal tf either
intrajugularly in which ca.e the external jugular vein was
exposed tor that purpose, or intraventricularly. In the latter
case a small hole {IX} 0. 2 ) wal drilled out in the skull and
26 gauge needle was inserted into the brain ventricle.

When

injecting the drug, spinal fluid of a volume equal to that to
be injeoted was withdrawn.
IV.

Preparation for tbe liver inoubatioq'
Duboi. technique (24) tor liver inCUbation ot the organo-

phosphorus compound. wa. tollowed.

The incubation medium for in

vitro studies contained the following components ia the conoentrations indioated: Dog liver homogenate 2.$ percent; dlpho.phopyridine nucleotide (DPN) 0.1 peroent, nicotinamide lXlO- 3 M,
and phosphate buffer at pH 7.2.
excluded from the medium.

In oertain experiments DPN was

The inoubation medium

to~

the in vivo

study oontained the following components: EPN, 1 mg/gm liver
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homogenate and Malathion, 100 mg/gm liver homogenate; DPN 0.8
percent; nicotinamide 8xIO-3 MJ and phosphate buffer at pH 7.2.
Usually, EPN and Malathion were incubated for 2$ to 30 minutes
at 38 0 C then added to brain homogenate in vitro or injeoted
into the "upper animal".
The

ooncent~atlon

of EPN (lmg/gm) waa seleoted so as to

inhibit only the liver enzyme 1n its inCUbation medium and not
to protect Malathion detoxification by ita own medium when EPN
and Malathion were used in combination following incubation, in
vitro or in vivo.

In tact, the oono.ntration used inhibited

about 90 percent ot the liver detoxifying enzymes (65).

In

80me in.tance., difterent concentrations of EPN and Malathion
were allO used.
V.

Dl1ution technique'
The inhibited brain homogenate was dl1uted tour or more

time..

Solutions ot varlous dilutions were analyzed to determine

their ChE aotivity and percentual inhibltlon ot OhE obtained
at various dilutions va. compared.
VI.

Diallsis techn1gue:
Microdlaly.i8 technique a. de.cribed by Craig (20) V&I

used.

Pho.phonate-inhibited brain homogenate was placed into

a dlalY8is bag.

Inside thIs bag a glasl rod smaller in diameter

than the dialysis bag was placed so that the layer of the
dialyzed solution (inner medium) would be of very small thickness
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Dialysis bag and its contents were placed in a container having
bicarbonate buffer (outer medium) identical with that used for
homogenizing the brain.

This allowed better exchange of ions

between the outer and the inner media, and eliminated the
necessity of stirring (20).

Dialysis was carried out for a

period of 12 to 12 hours and the brain tissue was analyzed to
determine its ChE activity before and after dialysis.
VII.

Preparation for manometrio analzsis:
1.

Procedure:
calibration waa made for each Warburg flask and its

manometer, and the flask oonstant "Kif waa calculated.

Homogen-

ates were diluted in bicarbonate buffer containing 0.02$ M Na
bicarbonate and 0.005 M MgC1Z.

Bicarbonate was gased from a

cylinder containing a mixture of 5 percent CO 2 and 95 percent N2.
lX10- 3 MAch and lxlO-2 M Bzch were the substrates used to
determine AcOhE and BuChE activities respectively (cf. August.
insson, 1951).

The brain tissues analyzed were gray and' white

matter of the oortex and of the medulla.

Forty five to $0 mg

brain tissue homogenates, in 2.1$ ml of the bicarbonate bufter
were plaoed in the main oompartment ot the Warburg flask.
final volume ot solution in each flask was .3 ml.

The

A flaak

containing only bioarbonate buffer ana the substrate and another
flask serving a. thermobarometer and oontaining .3 ml of water
were included in all experimental series.

All the flasks were
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then conneoted to their manometers and placed in water bath at

38 0 C.

EquIlIbration was oarried out tor 15 minutes, the C02

and the N2 gas mixture was bubbled through for 5 minutes, the
air trapped inside the manometers was then expelled and all air
vents ot the tlasks closed.

BrodIe solution was adjusted in the

right arms ot the manometers at the 150 ml mark and zero readings
in the lett arms ot the manometers taken.

The substrate was

then tipped into the main oompartments ot the flasks and the
shaking motor ot the machine turned on.

Manometers were read

ot.~60

minutes, solution was

eve:ry 5 to 10 minute. tor a total

adjusted in the right arm at the 150 mark and the left arm level
itleuured.
2.

Numerical example of the analytical results:
Pig. 3 show. the evolution ot CO

2

during 60 minutes

period in the oase ot 100 mg homogenates 01' cortical gray matter
and ot medulla, Aeh substrate.

The oaloulation ot the tlasks

constant "Ke02 " and ot the C02 evolved were carried out as
tollows.
a.

The calculation at the tlask constant tor

C~2 I

(flask volume in p.l - tluid volume in ,Ill) X t + fti
+ (fluid volume in p.1X 0<: CO2 )
pO

gas volume in pl •

.!fl.+ tluid volume in pl.

Q'C

C02
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)JL CO 2

EVOLVED
180

x MEDULLA
• CORTEX
x

•

10

20

30

40

50

MINUTES

FltJJRE .3
Jm>ROLYSIS OP ACH BY BRAIN CBB

60
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KC02 = tluk: oon.tant tor C02 gu

ot02 - 0.S67

at 37° C

= 273 + ,

'f

_ 'f0 1" t

pO

= 10.,000

Fluid volume

b.

=)000 pl

The oaloulat10n of C02 .volved 1n

p~t1me/dry

welght

of tl.sue (Aoh substrate)'
F1.. k #1

Flalt #2 Flaak 113

'lb......

.f.'.

_om.ter
(<<f.B.)

A

Bl0&1'bon- Conloal MedulluJ
.

It =

Man_.trl0 dltterencel
40 minut ••

Flaak

7

1.8

ts..8ue

tl.aue

It = 2.0

K

=2.0

12

43

99

T.B. subtraotion

S

36

92

Mult1plloatlon b.1 Ke02

9

72

184

Corr.otlon to.. non-

ensJa!e hl4PolJ.18

6,

17S

ot .lob

Pal COallOO
40 m1fiute.

67.5

as drJ tl•• u';

To .auve tile Tul&b11t'1 of blMb.eJd.oal data, a

statl.tlcal analrsi. ... oarrle. out with regapd to cortieal and
medull8l",. OnE acttnty (Table 1).

Fitteen dog. wer. atudied In

tb1. aerlea ot experiment. over .. p ..lod ot 1 y.ar.

0". ot eacb dog .3 to 6 det...lnatlon.
cortloal enZ7118
averaged.

w.~.

In the

ot the medullar,. and

made with Ach ... substrate and the r ••ult.

Tbe variabilit,. ot 6 determlnattons from tbe ....
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15 doga the value.
aotivity were 27.6 ± 0.46 and

animal was ± 0.06 p1 C02' in tne caee of all
tor cortical and medullary ebE

64 ± 0.71 pl C02. Thu. tne variability ot tne manometric data
tor

15 animal. over a period of one year waa le88 than

2.0

percent lndicating hlgh reliabilIty ot the method.

'lABLE t
STATISTICAL ANALYSIS OF BRAIN CBE

ACl'IVITY Dm'ERMINED IN NOBMAL ANES....
THETIZED A.NIMALS. ACH SUBSTRATE

1.$ DOGS. IN THIS EXPEBDtD'l' AND II'
ALL THE SUCCB:BnN'G ONES EACH SAMPLE
WAS DUPLICATED.

Plot eOa/100 mg dry
vt. ot eOl'tical
ti88ue/ 40 minute8

Plot C02 evolved/100
as drr wt. ot .edullaP1 t18.ue/40 minutes

28 • .$
)1.5

26.5

26.0

26.$
26.0
26.0
28.0
28.0
26.0
27.0
28.0
29.0
26.0
)1.0
Tne mean

27.6

Standard
deviation

± 0.46

± 0.71

OHAPTER III

EXPERIMENTAL RESULTS
I.

In vitro Itudy:
1.

Enzl!atio inhibition hi non-inoubated and liverincubated EPK:
Di~t.r8nt

conoentration. of non-incubated EPN were added

in vitro to brain homogenate.

Also EPN inoubated with liver

homogenate with DPN added, al well as EPN incubated with liver
homogenate alone were adaed to
in Fig.

4,

bra1n~homogenate.

As indicated

non-inoubated EPN haa weak inhibitory action on brain

ObE in vitro, while percentual inhibition of OnE wal much higher
when EPN was incubated with liver and DPN.

On the other hand,

there was no definite inore... in anticholinelterase activity ot
EPN when this compound waa incubated without DPN.
2.

Irrever8ibikity ot the CbE Inb.ibite4 by EPN:
The character ot the interaction betw.en EPH and the

enzyme OnE ... studied by 'e.ting the irreversibility of their
bonding compl...

PhJlical rather than chemical meanl were us.d

for thia purpose, namely,
a.

Dikution tecnniguel
The resultl or tb1a study are shown in Fig.

5. They

indioate that dilution hal no errect on the bonding between EPN
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IRREVERSIBILITY TESTS FOR EPN-OHE INfRRACTION
EACH POINT REPRESENTS AN AVERAGE VAWE OF THREE
DETERMINATIONS FROM THREE DOGS. ACB SUBSTRATE.
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and CbE irrespeotive ot EPN oonoentration.
b.

Diallsis technique.
The

a~~aohment

by dialyais ot trom

24

between EPN and CbE waa not destroyed

to 72 hours (Fig.

~)f

luggesting again

that EPN inhibited brain ObE irreversibly.
The results listed under Ca> and (b) indleate the
rellability ot the bioohemical determinations carried out in vivo

3. Enzl!atl0 inhlbition bI non-!ncubated and bi liverIngubated M'tathionl
Malathion alone, as well as Malathion incubated with
liver homogenate waa added in ditterent ooncentrations to brain
homogenates.

The ettects on brain ebE are shown in Fig. 6.

Malathion inhibited brain ObE at the I~o ot 0.8 ~ 10-5 MJ inhibit
ion ot CbE was higher when Malathion vaa not incubated than when
it waS incubated with liver homogenate.
alao (Fig. 6) that

M~athion

'fhe results indioate

loat it. aotivity to the a ..e extent

whether it was incubated with live. homogenate or with liver
homogenate and DPN.

4.

Malatg10g ina!tlvatiog bl liver homosenate.
To study the rat. ot Malathion inactivation by the liver

Malathion val incubated with dog liver homogenate in a conoentration of

50

mg/gm liver.

and 30 minutes.

Incubation was carried out tor 0,

Atter each period, the incubated Malathion

added to brain homogenate and brain CbE activity determined.
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PIGURE 6
IN VITRO INHIBITION' OF BRAD CBE BY LIVERINCUBATED Alm I'ON-IliCUBATED MALATHION.
EACH POINT REPRESElfTS AN AVERAGE VAmE OF
FOUR DETERMINATIONS FROM FOUR DOGS.
ACH SUBSTRATE.

4S
zero time, Malathion inhibited 80 percent ot the brain OhE, while
atter 30 minutes ot incubation with liver homogenate it inhibited
only 34 peroent ot brain Ohl (Table 2).

Thus, when Malathion-

liver ratio i. about 1120 Malathion "halt lite" is about halt
hour.

This sugg•• ta a relatively rapid destruotion ot Malathion

by the liver enzyme.

s.

Malathion-CbE interaetionl
A. was done with lPN, d1alysi. and dilution technique.

were used to study the type ot interaotion ot Malathion with
brain OnE in vitro.
a.

DI1utiog technique.
The results ot this study shown in Fig. 7 indicate

that tne binding between the inhibItor and CnE waa not de.troyed
by dIlution.
b.

Thi. sugge.ted an irrever.ible type ot interaction.
Diall.is tecan11e••
The result. shown in Fig. 1, oonfirmed the ob.ervation

obtained by the dilution technique, ot the lrrever.1bil1ty ot
Malathion inhibition ot Brain OnE.

Again thl. shows the rell.,

ability ot the method used tor measuring in vivo inhibit10n by
Malathion.

Moreover, thea. data in conjunotion with similar

results obtained with EPN, indicate at least a certain degree ot
similarity between EPN and Malathion with regard to the type ot
their interaction with CbE.
6.

In vitro anticholin,ste£a.e ettect ot combined

addit1~n
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TABLE II
MALATHION INAO'1'IVATION BY LIVER HOHOGEIATE
IN VITRO. EACH VAWE REPRESENTS AN AVEBAGE
VAWE OF FOUR ANIMALS.

Time ot incubation
in minutes

Percent ObE inhibition
in vitro (Ach substrate)

o

80

5
15

70

56
34

30
ot EPI and Mala'B&on.
a.

Combination of tne non-incubate. compounds:
Non-inoubated EPN and Halathion were added in vitro

to brain homogenate, aing11 .a ..11 as 1ft oombination.

Atter 30

to 60 minut •• the activitJ of brain CbE was determined uaing Ach
substrate in each oase, trom which extent ot inhibition was
calculated.

Table 3 and Fig, 8 ahow percentual inhibition of

brain CbE re.ulting trom cambiae. ettect of ditterent concentration ot EPN ud Malathion.

It appeued that the ettect ot

combination of non-incubated compounds in vitro waa .ere17 additive.

In

tact, in certain ca.e. ObE inhibition produced was

somewhat le.8 than additive (Table 3).

It .eemed that when high

concentration ot Malathion was added in combination with EPN to
brain homogenate, the inhibition appeared to be equal to ObE
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IN VITRO tlHIBITION OF BRlDl CBE BY
EP:W AND MALATHION AND THEIR COMBI1fA!IOlf
EACH VALUE REPRESENTS AN AVERAGE VAWE

OF FOUR DOGS. ACH SUBSTRATE.

Percent ChE inhibItion bJs
EPN 01'
EPN and
Malathion
Ma.lathion
sIngly
cOJlb1Datlon

The eompound

Ooncentration

Malathion

).2

10-Sr-t

80

EPH

4.0 10·~

:to

Malathion

2.2

10·Sx

80

EPN

2.0

10-~

$0

Malathion

2.0

10-~

78

EPN

7.5 lO-~

2$

Malathion

BPI

0.2 10·5M
6.5 lO·$X

42
28

80

95

8$

68
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FlOOD 8
IN VITRO EFFECTS, ON BRAIN ORE, OF COMBINATION
OF NON-INCUBATED OOMPOUNDS. ACB SUBSTRATE.
EACH VAtUE REPRESENTS AN AVERAGE OF FOUR
DETERMINATIONS FROM FOUR DOGS.

so
inhibition produced by Malathion alone.

This may be due to

Malathion having higher atfinity to brain ahE than EPN. and
preventing the action ot EPN at

ce~ta1n

sites ot CbE molecule.

It may be a180 that the CbE inhibition br EPI i. a alow process
allowing therefore !4alathion etrect to predominate at the time
(30 to 60 minute.) that the reading was taken.

b.

Combination ot liver-inoubated oOBPounda.
EPN incubated with liver and DPN and liver-incubated

Malathion were added to brain homogenate lingly and in combination.

The activitf ot brain ehE

inh1bltion caloulated.

va"~tben

detel'lllined and it.

The rHults obtained (Fig. 9) indioate

that combination ot EPN incubated with liver and DPN and liverincubated Malathion resulted in a potentiation in vitro of the
brain CbE inhibition.

Thi. might b. explained by Cook t • theory

it we were to assume that EPH inhIbIts detoxifIcation ot Malathion by the liver homogenate added in vitro in th•• e experiments
However the question arises as to whether or not thia
il the only mechanism that functions here.

Potentiation occurad

also when incubated MalathioD wal added to brain homogenate
atter the addition ot ErN.

The concentration ot lIver Incubate4

with Malathion val selected so that moat Malathion should have
been deatroyed.
vaa selected

10

The concentration of EPN (0.2 to 0.8 mg/gm liver
as to inhibit the liver enzyme in its own

incubation medium and not to protect detoxification of Malathion
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"ICIlB 9
IN VITRO EPFBCTS # ON BRAn CRE, OF aOHBINATIOlf
OF DIP'FBREN'r CONCEITRATIONS OF LIVER-IN'OOBATBl>
AND NOlf-INOOBATED COMPOUNDS. ACH SUBSTRATE.
BAOH VAWE REPRESENTS AN AVERAGE OF POOR

DETERMINATIONS FROM FOUR DOGS.

S2
br ita own medium atter combination with EPN sample; indeed, at
the.e concentration of EPN inhibition ot

the~alath1ona•• •

ot

it. own homogenate wal inoomplete and no EPN wal lett over to
protect Malathion trom detoxitioation (or. P. 33)
The pertinent reaults were as tollows:
lS percent brain abE inhibition br EPN, 0.8 mg/gm liver
12 percent brain CbE inhibition br Malathion, 20 mg/gm liver

6S percent brain ebE inhibition br EPN-Halathion combination.
When ooncentration or Halathion was kept con.tant and
EPN concentration waa lowered,

4

per~ent

poten~jation

Itill occuredl

brain CbE inhibition br EPN, 0.2 mg/gm liver

12 percent brain ChE inhibition by Malathion, 20 mg/gm liver

40 peroent brain ebE inhibition by lPN-Malathion combination.
II.

In vivo studie!1
A.

Sinsle administration:

1. 81gsle I,V. administration I
a.

ltV. a4m1niatration ot IPNl
A 'iatamatie Itudy ot the in vivo etreota ot

and ot it. dose-ettect relationship was oarried out.
ertective and lethal do.es were also u.ed.

EP.

Non

Fig. 10 indicatea

that EPN exerts in vivo anticholineateraae etrect on brain enzyme,
and that thIs action tollows a clear cut dose-errect relationship.
EPN appeared as a rather in vivo potent inhibitor and ita anticholine.terase ettect tirst appeared at a dose or 2 to 3 mg/Kg
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(Ninety to 100 peroent inhibition vaa obtained with 10 to 12 mg/
Kg) ot EPN.
Table

4

ahows the antioholine.terase etteot ot

EPN with respect to the death trequency in anesthetized dogs.
The death caused by toxic doa.s seemed to parallel fair ely close
the level ot inhibition ot brain AcChE.

Death did not oocur

until the inhibition reaohed about 90 percent of the normal
aotivitJ ot the enzJme.

Cholinergic symptoms suoh as deteoation

salivation. muscle twitohea, convulsions and respiratory embarrassment were observed witp lethal

d~8e.

ot EPN, milder oholin-

ergic symptoms al.o were observed with lower etteotive doses ot
EPN (Awad and Karozmar.8).

were
Brain samples trom animals given EPN I.V. added to
were ~
brain lample trom untreated animal, the two samplel A then homo-

gen1zed together and CbE activity me.lured 1n this mixed sample.
In this ca.e the enzJme ot the untreated brain lample was not
inhibited .1 ,hown im Table

5. This indioatea that no tree

phosphonate compound, were present in the brain tissue, ot animal
given EPH in vivo.
b.

l,V, admini,tration ot Ma,athionl

In a similar way experiments were carried out
with Malathion.

Fig. 11 indicates that Malathion has an anti-

cholinesterase etteet on brain enzyme in vivo which tollows a
clear cut dose-ettect relationship.

Malathion 1s a weak inhibit-
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TABLE IV
LETHALITY AND BRAIN CBE INHIBITION BI
EPN AND MALATHION ON I. V. ADMINISTRATION. ACH SUBSTRATE.

Compound

Do.e in
mg/Kg

Percent CbE inhibition
(average value.)
Cortex

EPlf

MalathioD

Death

!

Medulla

Ii

$0

0/5

14

0/6

10

90

20

100

100

2/5
2/2

10

0

0

50

10

0

100

25

18

0/4

200

50

38

0/6

i ',1

,300

60

1/4

1/:1

400

12

51
65

.3

,30

5

50

10

..

j
II!
,Iii

i,l

l

I

0/2
Iii

3/3

I
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TABLE V
DETERMINATION OF HOMOGENIZATION EFFECT
-IF ANY- ON PERCENT INHIBITION OF CD
EACH VAWE REPRESENTS AN AVERAGE VALUE
OF THREE DOGS. ACH SUBSTRATE.

Brain tissue
Brain tissue treated
wi th EPN (12 mg/Kg)
1:1 ot brain tissue
treated with EPN •
brain tissue untreated
homogeniaed together

Peroent InhibitIon ot brain ObE

100

41

100
0/. INHIBITION

OF ACHE

80
o

60

.

/'

/

40

20

x MEDULLA

o

o

o

L/~~~

10

40

CORTEX

__~~________________________
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FlOORE 11
IN VIVO, DOSE-EFFECT RELATIONSHIP OF MALATHION'
01' BRAllf ORE. EAOH POINT REPRESENTS AN' J.VERAGB
VALUE FROM SIX DOGS. ACH SUBSTRATE.

.$8

or wnen compared to EPNJ its anticholinesterase ettect tirst
appeared at a dose level of about
inhibition of

65

50 to 60 ms/Kg. Maximum

to 70 percent was noticed with doses ot 400 mg

/Kg.
Cholinergic symptoms were also observed wIth
lethal al well aa with effective dosea of Malathion.
t,. depended on how large a dose

'Vias

given.

Table

The

aeverI~

4 shows the

relationship between brain CbE inhibition and lethality; it
appeared that death did not occur until the do.e of about 400 mg

/Kg ot

Malathion in the ane8thetiz.d·~an1mal..

Aa atated, at that

time residual activity of CbE wal still relatively high.
2.

In vivo interaction ot EPN and Malathion with brain

-ToCbEldetermine the degree ot irreversibility of the
CbE inhibition produced br EPN and br Malathion in vivo, the
dialyaia teohnique was used.

Table 6 show. that the in vivo

inhibition by EPN was not reversed by dial,..is, irre.pective ot
dose.

Similar type of irreversible interaction occurs in vivo

between Malathion and CbE (Table 7).

The.e re.ulta •• well u

the data on irreversibility ot interaction between EPN and Malathion in vitro indicate that the meaaurment ot the in vivo inhlbition is a faithful indioation ot the actual inhibition in
the animal which was not reversed or modified by the prooedure.

3. Eftects of BPN and Mllathion on true and pseudA CbE
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TABLE VI
EFPECf OF DIALYSIS Olf THE III VIVO BPN'..
BRAIN CBE INHIBITION. ACH SUBSTRATE
EACH VAIDE REPRESENTS AN AVERAGE VAWE
OF THREE DOGS.

Do.. ot EPN

mg/Kg

Brain
Ti8.ue

Percent CbE inhibition
Betore
Atter
Atter
dialY8il: Z4 hours 72 hours
d1al,81. d1a1Y8i.

8

Cortex

S3

So

Medulla

70

72

Oortex

68

70

66

Medulla

80

79

81

60
TABLE VII
EFFEC'l' OF DIALYSIS ON THE IN VIVO MALATHIO.
BRAIN OBE INHIBITION. AOH SUBSTRATE.
EACH VAWE REPRESENTS AN AVERAGE VAWE OF
THREE DOGS.

Do.e of
Malathion

Brain
tis8ue

Percent abE inhibition

l1lg/Kg

Betox-e
dialysis

.

.

SO
100

Aft.x24 hour.
dialysis

Oortex

11

10

Cortex

28

28

Medulla

17

IS

Atter
72 houri
dialysi •
8

61

ot the blood.
Three mg/Kg ot EPN vas glven I. V. to the whole anesthetlzed animal.

An hour later, a blood s ..ple was wlthdrawn and

analyzed tor 1t. plaaaa BuChE and RBC AcCnE actlylt1es, using
Baoh and Ach substrate..

S1xty mg/Xg ot Malathion was injected

similarly and blood activities ot

abE'.

were determined.

The

re.ult. ahown in table 8 indicate that EPN inhibited RBC enzyme
more than plasma ChE, while Malathion inhibited plasma enzyme
somewhat more than

4.

eo enzyme.

Sins,e adminiltration in"jthe Mupper anyal ft ,
The purpose ot the study of the "upper animal" waa

to determine whether or not metaboli.m 1. nece.eary tor the
activity ot EPN and Malathion

&I

well

AI

tor thelr potentlatlv.

ettect to occur in vlvo.
a.

Intrajugular adm1ni.tratign.
i.

Non-incubated and Aiyer-ineubated EPI.
Various dose. ot EPN were administered into

the jugular vein in the "upper animal".

Brain ti.8ue

analyzed to determine it. ObE activity.

The ettecte ot ElK on

Wal

then

brain enzyme when given into the jugular vein to the ·upper
animal" can be compared (Table 9) with. 1ts action when EPlf va.
given 1nt' the temoral vein to the normal animal.

It appeared

that at a dose of 1.5 mg/Kg EPN produoed lome brain ChE inhlbitl0
when injected into the normal aneethetized animal and had no
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TABLE VIII

EFFECTS OF EPN' AID MALATHION ON TRUE

A.ND PSEUDO ORE OF THE BLOOD IN VIVO.
EACH VAWE REPRESENT AJl AVERAGE VAWE
OF THREE ANIMALS.

Do.. ot compound
in ms/Kg

Percent ot CnE inhibition

RBO

Pluma

eAch ,ub.trate)(Bzch .ubatrate)
EPIi',

3

ms/Kg

Malathion,
60 mg/Kg

6)
32

33

6.3
TABLE IX
EFFBCTS OF BPN GIVD I. V. AliI) IftRAJUOCfLARLY TO NORMAL AND "UPPER"
ANESTmID.'IZF.D ANIMALS RESPECTIVELY.
EACH VAIlJE REPRF:SENTS AN AVERAGE VALUE
OF FIVE At"lIHALS. ACH SUBSTRATE.

Brain ObE activitr
Oontrol = IOO

Do.e in
lis/Kg

Given I.V. to normal
ane.thetized animal

Given intrajugularlr
": to "upper anim~l"
Non-incubated

10.0

Incubated

cortex

Medulla

Cort.

90

116

100

110

92

129

,30

10

100

100

12

So
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.tt.ct wh.n injected into the ·upper animal·) 1a the latter

0...

ErN did not oiroulate through the animal'. low.r part and 1ta
At a dose ot 10 mg/lg EPN produced about 70 to

viaceral organ..

90 peroent brain ebE tnhlbition when Injected into the normal
animal, and bad again no ett•• t when given to the ·upper animal".
From this oomparilon it ..... again that EPN had to be metabolized, pre.umably in the liver, in order that it can ex.rt ita
anticholinesterase ette.t in y1yo.
To tind out more about this phenomenon other
.erie. ot experiment. were carried oQt with variou. do.es ot
liver-incubated EPN given via the jugular vein to the "upper
animal".

Five experiment. were carried out with a dose ot EPN

1.5 .g/Xg and 10 ms/Kg. Table 9 shows that tbe incubated EP.
in a dose of 1.5 mg/Xg instead ot inhibiting, increa.ed brain
ot

CbE activity, particularly that ot the medulla.

A Itatistlcal

study has been done to asoertain the occurenoe ot thi.
phenomenon.

The EPN dose used in this oa.e was 1.0 ms/Kg.

10 shows the result. ot this analysis.

Tabl.

The increa•• in brain

CbE activity tound in this serie. ot 7 experiments vas stati.tically significant.
11.

won-incubated and llver-incubated Malathiona
Experiments similar to the above were carri-

ed out wlth Malathion 1n the "upper animal".

Non-incubated and

liver-incubated Malathion was a4m1niatered into the jugular vein.

TABLE X

STATISTICAL ANALYSIS OF MEDULLAR! CBE
AO'fIVATIOll BY INtXfBATED EPN, IMG/KG

ADMINISTERED IftRAJU OOLARLY.
EACH VAWE REPRESEN'TS All AVERAGE OF

TWO DEfERMINATIONS. ACH

~JBSTRATE.

P1 of C~ ev01v84/40
minutea 0 ag brain
ti.aue (EP1f treated)

P1 of C~ ev01ve4/40
minutes O.g b~ain
ti.aue (untreated)
.,

,32.25
31 • .50
32.25
28.25
,32.50
.34.00
.34.00
The mean

standard
deviation

95% CL.
Brain ChE

ntH

42.70

41.50
47.50

42.50

45.$0
46.50

,32.10

45.50

0.60

0.80

,32.1± 1.4

45.5 ± 1.9

lO~

aotivity

4.3.20

141.5~

IS SIGNIFICAN'l' AT THE O.O~ LEVEL
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Brain ti.sue was anallzed in each ca.e to determine it. CbE aotivit1.

SO

Th. r.sults obtain •• (Table 11) indicate that Mala,hion.

to 100 mg/Xg.had anticholine.tera.e actions when inject ••

I.V. to the normal ane.thetize. animal.

fbi• •ttect wa. more

pronounced when non-incubated Malathion was given intrajugularly
to the "upper animal" at the .ame d08e level in contradistinction
to the relult. obtaine. with EPN.

EYen at lower do.e level.

(Table 11) Malathion inhibite. brain CbE when given intrajugular17 to the ·upper animal".

Incubation with liver homogenate

reduced anticholine.terase activitl bt Malathion, again contrar7
to the result. obtained bJ EPN.

Thus, liver metaboliam of

Malathion ..... instrumental in the weak potencl ot Malathion as
anticholine.tera.e agent when given I.V. to the normal ane.rinal17, unlike BPI, at do.e le•• l .. low a.

thetized animal.

10 mg/Kg and .. high al 100 mg/Kg Malathion did not produce
activation ot CbE, onlf inhibition val ob.erve. with minimal
ettective do ••••
b.

Intraventric91ar admini.tration ••
i.

Xon-incubate. and liver-incubate. EPN:
The purpole ot u.ing this route of adminil-

tration vas to determine whether or not blood-brain barrier has
anr ett.ct on ErN action.

ErN incubated with liver and DPN al

well as non-incubat.d EPN were injected into the brain ventricle

ot the ·upper animal".

Re.ult. obtaine. (Table 12) indicate that
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'fABLE XI

EEFECTS OF MALATHION GIVEN I. V. AND
II'fRAJUOOLARLY TO NORMAL AND "UPPER"
AIES'fHftIZED AlfDlALS RESPECTIVELY.
EAOH VAUJE REPRESENTS AI' AVERAGE VAWE

OF PIVE ANIMALS. ACH SUBSTRATE.

Ptredet brain CbI 1Dhlb1tlon

Do.e in
mg/Xg

Given I.V. to normal
anesthetlzed anlmal

Glven Intrajugu~ar11
to "upper an11lal"
Bon-incubated

Cortex

Medulla

10

o

o

2.$

o

o

So

8

o

100

22

Cort.

Med.

Incubated
Cort. Med.

o

o

o

7

6

o

2,$

1,$

12

o

34

20

22

10

2
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TABLE XII

I:FPEC'l'S ON' BRAII' CBE Bf EPN AIJ1INISTERED
BI 'rH'REE DIFFEBDf ROOTES • .loa SUBSTRATB.

EAOH VALUE REPRESENTS D

AVERAGE OF THREE

UIHALS.

Boute ot
Do.. 1n
adm1niltrat1on mg/xg

Brain ObE &ctlv1t7
Oontrol = 100

Cortex
Non-ineub.

Medulla
Incub.

Non-1ncub.

In cub.

0.5

100

80

112

110

10.0

100

69

100

52

ve

1.5

100

92

110

Femoral
vein

1.5

Brain
ventlticle

eU •.1.)

l!fnulU

eU •.1.)

(N.A. )

90

U • .1. INDICATES "UPPER A..1'ifIMAL"
N'... INDICATES NORMAL ANIMAL
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non-inoubated ErN at a do.e of 10 .g/Kg produo.d no inhibition ot
brain ebB when administer.d intrav.ntrioularly.

It ahould be

born In mind that thia do.e produced 70 to 90 percent inhibition

ot brain CbB wnen admini.tered I.V. to nor.a1 anesthetized anlmal
Liv.r-ineubated EPN in a do.e ot

0.5 .g/Kg given intraventrieul

lJ produce. greater in.r.... ot CbB activity (Table 12) than that
produced by 1ntra3ugulap admini.tration ot a do.e ot 0.$ ag/Xg.
Larger do••• of BPR produced brain CnE Inhibition (Table 12).
provid.. liver-incubat.d EPN val employed.
,..he.e data •• well as the rellult. obtaine.
upon I.V. administration ot EPN to the ·upper aat.al" (ot. above,
••otion 4) ,ugse.t that BPH m.tabolis. 1. neoe•• ary tor 1ta aotlvatloD a. an aDtloholine.tera.e rather than to lmprov-e'
capacitJ to penetrate blood-brain barrier.

it.

Whether slven intra-

ventricularly or I.V. in the ·upper animal" ErN inhlbit. aore
after incubation, paptio\1lulr in the tone. o.. e bloocl-braiD
barrier .sa by-passe. and Jet the oompound inhibit.. ..pendiDg
on It. activation in the 1lvor.
11.

Non-1g,uba,0. a.n4 liver-1goubated l!&atb1oas
Liver-1Doubated Malathion and non-incubated

Kalathion were a_inlstered bto the brain ventricle ot tbe
"upper animal".

EYen halt ot the d••• ot Don-incubated Kalathion

whicb was inefte.tive when admini.ter•• I.V. to tbe whole

an~al

inhibited brain CnE when adminlatered intraventrioularly iDto

10
the uupper animal u (Table 13).

Here also as in the in vitro

experimenta, liver incubation reduced the anticholinestera.e
activity ot Malathion.

ObE inhibition bJ non-inoubated Malathion

given to tbe ·upper animal" va. almo.t equal quantitatively bJ
both intrajugular and intraventricular rout •• , Malathion at

m&/Kg produced 16 and

14

25

percent inhibition of cortical ObE

wham given into the ventricle or via tbe jUgular route re.peetive
lYe

The•• data lugge.t that blood-brain barrier has no control

over Malathion action.

Allo tbe ettects were generally aimilar

upon 1ntrajugular and 1ntraventriculera4m1nistratlon& ot liverinoubated Malathion.

However, the choice ot the rout •• eemed

to influence the distribution ot Malathion.

When given intr-

ventricularlJ, Malathion inhibited medullary enzyme more than
the cortieal enz1lle vhile when administered I.V. ato either
normal or uupper anlmal u it inbibited cortioal more than the
medullary enzyme.

Tb11 dependance on the route ot .eleotivity

ot aetion ot Malathion toward ObE of ditterent parts of tbe brain
il not under.tood (ct. Discul.ion).

5. T1!e·ertegt relationship or small do... of ErR and
ot Ha,atb&oQ. I4Ilni,t!red *&~.f
The indication obtained above that EPN siven via
intraJugular and intraventricular routel

cause~

at low dOle level

inereaae in CbE a.otivlty urged more careful study ot EPN errect

given by the I.V. route in normal anesthetized animal.

Similar
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TABLE XIXI

EFFEC'l'S ON BRAIN CRE BY MALATHION
ADMDfIS'l'ERED BI THREE DIFFERENT ROUTES
EACH VA-WE REPRESENTS AN AVERAGE VAWB

OF THREE ANIMALS • .lOll SUBSTRATE.

Percent CbE inhibItion

Do.e in
Route ot
adminI.tratlon Jlg/Xg

Medulla

Cortez
lfon-incub.!Incub.
Brain
ventricle

lfon-incub.

Irlcub.

25

16

10

28

16

25

14

7

9

0

(U • .1.)

SO

as

12

15

0

Femoral
veln
(N.A.)

50

(U .A.)

Jugular
vea

8

U •.1. IIDICATES "O'PPER ANIMAL"
N.A. INDICATES NORKAL ANIMAL

0

12
atudy was alao carried out in the ca•• ot Malathion.
a.

Time-etteot ,elatlonahiE ot ElB,
EPK in a dO.8 ot 2. mg/Kg waa given I.V. to tne

normal anesthetized an1mal.

At difterent lengtb.a ot t1me atter

tne injeotion tne ant.al was sacrified and the brain was analyzed
tor ita OnE aotivity.

It appeared (Table

do.e. increa.ed tne activity

14) that EPW

rrle d L<.ll uX' I:
01' brain dhB.

"

in .mall

The inore•• e reached

its peak at 40 minutes, return to control or slight inhibition
tollowed.

The.e results were in agre.ment with those obtained

with ....11 dos.s ot EP. adminiatered,!into the "upper animal".
b.

Time-etteot relatiogshi, 91' Malathion,
Malathion in a

d~.e

I.V. to normal anesthe\lzed dog..

ot 10 to 100 .g/Ig waa given

An1mala were aacritied atter

ditterent t1me intervals. and brain CbE activity wal determined.
With emall do.e. ot Malathion (10 to

25

ms/lg) there

Wal

no

increase in ObE activity in the brain. alight inhibition occured
with larger dose (Table 15).

It could be caloulated from the

dose-etteot relation.hip ot EPlf and Malathion that 1 .g/Kg doa.
01'

the tormer whicb. aa seen activated the enz,.., was equi-

ettective with 45 mg/lg doee ot the latter which was inettecti.e
or eamvbat inhibitory.

Whenever Malathion cauaea inhibition it

was nearly constant tor more than two hours.
c.

:sttects ot EPlf and 01' Malathion on braip p,eydo

.!&II

73
TABLE XIV

Tnm",D'P'1JtO'l' DLA'l'IODKIP Olf BIUI CBE

OF :2. MG{XG OF BP:r GIVD I. V. TO NORMAL

AN'ESTBEflZED ANIMAL. ACH AND BZClI SUBSTRATE.
EACH VAWB REPUSElfl'S AN AVERAGE VAWE

OF THREE ANIKALS.

'l'1IIe at which
wain lamples
w.e taken
attap the
injection

Cortical actlvItr
Control 100

=

Hedullarr activIt1
Control 100

=

AcChB

BuChE

AoCbE

BuChE

20 minute.

95

85

12)

125

40

mInutes

75

85

131

140

75 .!.nut ••

60

70

112

106

150 mInute.

75

84

90
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TABLE "X)I

TIME-EFFECT RELATIOlfSHIP ON' BRAIB CHI OF

100 MGIKG OF MALATHION GIVBI I.V. TO

B'Omw, ANBSTRJJ:rIZED ANIMAL.
EACH VALUE IS AN AVERAGE VAmE 01' THREE
AlfIMALS • .lOa: AND BZCa: SUBSTRATES.

Cortleal inhibItion

Medullary InhibItion

we".. taken
att •• the
inje.tion

A.ahE

AcObB

20 minute.

22

Time at whioh
brain .ampl••

40 Ddnutea
90 minute.

22

BuCn:i

40

o

39

o

37

o

7S
TEds was studied in the course ot the investigations on EPl( and Malathion time-ettect relationshlp.

Table

~

indicates that EPN at small doses activates and at large doaes
inaotivates medullary brain pseudo CbB in parall.l with its
actioil upon brain AcChE.

In the cue ot Malathion there was only

inhibition ot pseudo CbE (BuChE) as well as ot AcOhE (Table 15).
In other words ettects ot EPN and Malathion on BuChE were always
analogical to those on AoCbE. whether in caae ot inhibition as
with EPN and Malathion or activation, as in the cue ot EP!l alone.
B.

Combined administrationt.
1.

I.V. rout.:
1'h1s study' was carried out to analyze the eftects ot

combination ot EPl( and Malathion on brain

ehE. EPI' wu adminis-

tered I.V. to animals in ditterent d08ea ranging from 1 to 10 mg
/tCg.

Omt halt hoUl' later, Malathion wu administered in doses

ranging trom 10 to 50 mg/Kg.
activity.

Brain tissue was analyzed for 0hE

Tabl. 16 shows pereent brain 0hE inhibition and the

death frequenoy with ditterent combined dose8 ot EPI and
Malathion.

To deaoribe more .peoifically the phenomenon ooouriag

with one dOS8 combination, the toxicologioal and enzymio ettects

at admin1stration ot 2 mg/Xg ot EPIl and 10 mg/Kg ot :Malathion
will be described.

Death ocoured within 10 minute. atter the

injection of the seoond oompound (Malathion) in about

85

peroent

of the treated animals, it waa preoeded by cholinergio symptoms

16
TABLE XVI
III VIVO IlfHIBI'1'ION OF BRAIN CBE UPON
COMBINED ADHINISTRATION OF DIFFERENT
SEQUEIiCES AND OF DIFFERENT DOSAGE RATIOS
OF EPN AND MALATHION'. ACH SUBSTRATE

Sequence ot
administration

Do. e in mg/Kg

Percent ebE inhibition Death
ratio
(Average valu.e.)
Medu.lla

cortex

.,

414

EPN prior to
118 Malatb.1on

50

80

BP:tr prior to
EPK 2 m,
Malathion
Malathion 10 ms

85

6S

EPlf aDd Malathion
Malathion 10 JIll .1111.11tarutoua ly

18

8

0/3

10

0

0/1

Malathion prior
EPN 10 mg
Malathioll SO JIlS to .,If

80

100

Malathion prior
m8 to EPH

69

68

M&latb.1on prior
EPlf 3 mg
Malatb.1on 60 ag to EPN'

62

68

BP:tr 1 ms
JIalathioD

So

EPN 2 mg

EPlf 2 m8
Halatb.1on 10

EPN .$ mS

Malathion

SO

ms

Malathion
prior to BPI

40 min

5/6

10 min

2/2

30 min

2/2

40 min

4/4

60 min

i,l

already described.
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Brain ObE inhibition was about 85 percent in

tne medulla and about 65 peroent in the oortex (Fig. 12).

In all

those ea... the blood ObE inhibition waa alwAJs complete while
brain enzyme inhibition was not.
A .imple algebraic equation was used (Table 17) to
ascertain whether this extent ot inhibition was due to additive
aotion or to potentiation.

The equation allowed the calculation

ot the oombined AED50 tor both compound. (AED50 is the
ette.tive dose producing

So

a. tor their oombination..

.v~age

percent inhibition ot ObE) as well
It appe&p. that a potenti.tive

inhibition .ocured sinee the combined AEDSO was much higher when
caloulated (91 mslKg) than when me.sured (51 ms/Kg, Table 17).
2.

the etteet ot various sesuen ••, on ooabtged I.V,
a..inia'rati!D.
Sinoe potentiation oooured when EPN vaa administered

prior to Malathion the

~estion

ari.e. as to whether or not

potentiation would al.o occur it the ••quen.e ot the combined
administration i. rever••d.

To answer thi. question tour

experimental .eri.. were carried out.
a.
~

ZP., 2 .allg, waa administered I.V. )0 minute.

10 mslXg ot Malathion
b.

EPN, 2 as/Xg, was admini.tered .1mu1taneou.1I

with 10 ms/Kg ot Malathion.
o.

EPN, 10 mg/Kg was admini.tered I.V. 50 minute.

atter Malathion,

So

mslXg
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100 ~--------------------_

% INHlalTlON
OF ACHI

eo

CORTEX

MEDULLA

I

l

10

40

20

I

o

IPN

E~N

MALATHION +EPN
MALATHION

MALATHION '~N

+

ttULAlHlON

FI(JJRE 12
EFFEO'1' ON BRAIN CHE BY COMBINATION OF COMPOUNDS
GIVEN I. V. TO THE NORMAL ANESTHE'fIZED ANIMAL
(EPN_ 2 MG/ltG GIVEN PRIOR TO MALATHIO., 10 KG/KG)
EACH VAWE REPRESENTS AN AVERAGE OF FIVE DOGS.
AeB SUBSTRATE.

19
TABLE XVII
MEASURED Alm CALCULATED AEDr;o IN MG/XG
OF COMBINED EPN AND MALATHION.
BlOH VAWB RRPRESEl'fS Alf AVERAGE VAWB
OF SIX ANIMALS. .lCB SUBSTRATE.

AEDso combined
.g/xg

in

Meuured

caloulated trom
tb.. equation

51

91.8

Cortex

TIm E'3JATION':
I

PBRCENT, RATIO EPN

IN OOMBINATION

---------------+

PERCENT RATIO. MALATllION
Dr OOHBlKATIOlf
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d.

EPN, lms/Kg was admlnlstered $0 to 120 mlnut ••

I.V., Itter Malathlon, 60 mg/Xg.
The r.sults ot those experiments are shown 1n
Fig. 1.3 and Table 16 and can be sWJUll81"ized as tollows:
i.

Cholinergio symptoms developed in all s.rie.

11.

Potentlation ot brain OhE inhIbition ocourea

ot experlment ••
in (e) and in (d) but not in .eries (a) and (b), 1.e .nen EPN,
2 mg/lg was glven simultaneous ely with or atter Malathion,
10

mg/Ig.

ill.

Lethality occured again in .eries (0) and

(d) but Dot in .erle. Ca) and Cb).

The tact that potentiation

ot toxicity and ot brain ObE inhlbltlon did not occur in .eri ••
ea) and (b) does not necessarily .ignify that the dose ot
Malathion in question (10 nag/Kg) was a•• troJed in the llver
wlthout havlng the chance ot being protected by EPN .ine.
Malathion at this particular dose glven Intrajugularly to the
·upper animal" and thus not a•• troyed by the liver, did not
produce a .ignifioant brain CbE inhlbition.
ly.

When ErN, 10 l'Ig/Xg Val giYen Itts Malathi_

( ••1'1•• 0) lethal1t1 maJ be due to toxio ettect ot EPN sinee at
thi. dose it .om.times produce. death.

BoweYer thi. does not

seem to be the only caus. ot death .inee potentiation ot both
lethality and the enzyme inhibition oocur.d al.o when minlmal
ettective dose ot EPN (.3 mg/Xg) was given prior to minimal
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%INHIBITII~
OF ACHE

80
CORTEX

MEDULLA

60

40

20

I
I

I
I
I
I
I

u ~--~~~~-~I~----~I~------~:~~____L-______~______~
MAlATHION.
il2HR, AFTER
EPN

EPN,I/2 HR.
AFTER
MALATHION

EPN,
MIXED WITH
MALATHION

FlGUU

MALATHION,
I/2HR.AFTER
EPN

EPN,I/2 HR.
AFTER
MALATHION

EPN.
MIXED WITH
MALATHION

13

EPFEO! OF THREE DIFFERENT SB!CPENCES OF COMBINED
ADMINISTRATION OF EPlf, 2 MG/XG AND MALATHION,
10 HG/XG. EACH VAmE REPRESENTS AN AVERAGE OF
THREE Dlfi'ERMINA.TIONS FROM THREE DOGS.
AOR SO''BSTRATE.
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ettective

d08~*)(60 mg/Eg) ot Malatbion.
y.

In ••rie. (d) in .pite of the tact that deatl

and potentiation of brain ObE inhibition occured the
not .s extenlive aa when EPN

Val

latte~

was

given prior to Malathion,

potentiation ot inhIbition ..ounted to 20 to )0 pereent above
value. expeoted on the ba.i. of pure addition.

vI;
prior to

EPN

In serl •• (d) in which MalatnioD was given

death occured within

tion ot the .eoond compound

(EPN)

minutes of the administra-

60

while when

EPN

waa given prior

"

to Malathion death occured at on17 1'to 10 minute. atter the

administration of the •• cond compound (Malathion).
Th. blochemieal data obtained in this s erie.

of experiments agree fair17 well with the pharmacological data
obtained in the same laboratory, aince potentiation ot pharmacodJUamic etfects was noticed in a study ot action. of EPN and
Malathion at specific neuroettector..

28 .g/Kg given 45 minutes prior to EPN.

For instance, Malathion

2.5 mg/Kg,

produced

inoreaa. ot ronacle re.ponse to indirect stimulation while
IJIalathlon and EPU given singl,-, produoed increased muacle twitch.e
at dOl •• of more than 2$0 and 12 mg/Xg respectively (Kaczmar.
Awad and Blachut, unpublished).
(*) fhe m1D1mum effective do.e i. the smallest do.e capable of
producing significant (~15 percent) inhibition.
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3.

Combined a.clm1nistration to the Ifupper
a.

Intrajugu*~f

i.

Non-incubated c9!R0und.:
In the ·upper animal" lPN,

W&I

an1Jaa~" t

0.5 to 2.0 mg/Kg

admini.tered into the jugula.r vein )0 minute. prior to

Malathion, 10 to 2$ mg/Kg.

14)

The results obtained (Fig.

indioate that non-incubated combined EPN and Malathion did not
produce potentiation at )0 minutes in the ·upper animal lf atter
the admini.tration of the second compound.

However at 60 minut.s

after their administration potentiation ot brain CbE inhibition
developed, particularly in the cortez.
il.

Liver-incubated cO!Poundl'
!PH ... incubated with liver and DPN and

administered via the jugulat- vein to the "upper animal" 30
minutes prior to administration of incubated Malath1on.

The

result, obta1ned (Table 18) ind1cate that potentiation ot abE
Inhibition was produced

)0

minute, after the adm1nistration ot

the second compound.
Potentiation occured alao htom combination
ot incubated EPB and non-incubate. Malathion (Table 19).

In

this experiment conditions tor de.truction ot Malathion were not
pre.ent, aince Malathion was administered without liv8r and
8inee EPN concentration was .eleoted
thion .. e" of it. own liver medium.

80 a8

to de. troy

~ala

Thus, potentiation in thi.
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IOOr-----------_________________________________

Six T Y ~INUTES

AFTER DRUG ADMINISTRATION

CORTFX

l__ _

--L -------________--'------_---.Ji~ __

o
% IN HI SITION

MEDULLA

EPN

I
MALATHI~ EPN

EPN

+

OF ACHE

MALATHION

MALATHION

100

(PN

+

MALATHION

.

IIIINETY MINUTES AFTER DRUG ADMINISTRATION
-

CORTEX

o

MEGULLA

I

'---:E::P=N--:-M:-AL-ATH=,O-N---Lf'-:-~----------------L--~
EPN

+
MALATHION

FIGURE

I

i ---- !- - MALATHION EPN

+

MALATHION
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EFFECT ON BRAIN CBE OF COMBINATION OF NONINCUBATED COMPOUNDS GIVEN INTRAJUOOLARLY TO
THE "UPPER ANIMAL" AT 60 AIm 90 MINUTES AF'l'ER
THEIR ADMINISTRATION (EPN, 2 MG/KG GIVEN )0
MIllTTES PRIOR TO MALATHION', 10 MG/KG).
EAOH VAWE REPRESENTS AN AVERAGE OF FIVE
DE'l'ERMINATION'S FROM FIVE DOGS. ACH SUBSTRATE.
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'fABLE XVIII
EFPEC'l' Oll' IN'l'1U.JU (JJ LAi OOMBINED

ADMINIS'1'RA'1'IOI OF Ell GIVEN HlLF
BCXJR PRIOR 'f0 MALATlIION IHO 'fBB
"UPPER ANIMAL" • .lOB SUBSTRATE.
BAOH VAWE REPRESENTS AN AVERAGE
VA-WE OF THREE ANIMALS.

Compound

Incubated

Bon-incubated

Brain ebE actiY1tJ
control = 100

Brain abE act1v1ty
control 100

=

Cortu

Malathion

ZS.O

EPN prior to
Malathion

25.0

0.5

Medulla

97

121

100

10.3

94

100

86

93

60

80

86
TABLE XIX

IftRAJO'GUUR EFFECT OF COMBINATION
OF EPN GIVEN TO THE "UPPER ANIMAL"
PRIOR TO 1l0lf-UCXTBATED MALA'l'HIOI'.
BACH VAWE IS AN AVERAGE VAlIfE OF
THREE dIMALS. ACH SUBSTRATE.

Brain OhE activity
oont1'ol = 100

Malathion,

2S

lIPll,

0.5

Halathioa,

25

Oorta

Xedulla

97

121

86

93

64
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oaae could not depend on proteotion afforded bJ EPW to Malathion
againat detoxification.
b.

IntraTentricular adminl,trat&o!!.
1.

NiP-intubate, qgmpounda.
In tbe "upper animal" !PH, 0.05 mg/Kg, was

injected into the brain ventricle 30 minute. prior to adminiatration of Malathion, S ms/Kg.

Tne re.ults (Table 20) .how

that at 30 minut.. atter tne injection ot the leeond compound
(EPN prior to Malathion) brain enzJ1De inhibItion wa. lOliewhat
"

greater than tba' expected on the baai. ot mere addItIve ettect ••
Thil again sugge.ta that potentiation doe. not nece.sarily depend
on protection ot Malathion by EPN.
ii.

LiTer-incubated eompount••
Ooncentration. ot ErN in the liver bomogenate

were .elected with the precaution mentioned earlier (ct. p. 3).
El. was incubated with liver in,pre.ence

ot DPI and given tntra-

ventricularl,. to the "upper animal". 30 minute. prior to Iiverincubate. Malathion.

The result. obtained (Table 20) indicate

that at 30 minute. atter the administration ot the .econd
compound (Malathion) potentiation ot brain OnE inhibition
occured.

Potentiation was much more pronounced than

'WIlier...

that~occur.d

at 60 minute. atter combined intraventricular administration of
the non-incubated compound ••
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TABLE XX

EPPECT OF INTRAVENTRIWLA.R ArtIINISTRATION '1'0 THE "UPPER ANIMAL" OF
EPlf GIVD PRIOB TO MALATHION.
EACH VAWE IS AN AVERAGE VAlUE OF
THREE AlfIMALS • .leH SUBSTRATE.

CompoW'ld

Non-lncubate4

Incubated

Do.e 1n
mr/Itg

Brain ObE aetivit1

oontrol

= 100

Brain ObE activity
oontrol = 100

cortex

EPlf

o.oS

Medulla

llS

s.oo
EPK prior to
Malathion

o.os

.$.00

60

70

100

100

96

92

80

80

O!IA.PTDl IV

DlSroSSIOI'
I.

IaSridYlt'IB'
Frawl.,. 1n 19S7 baa ahown that potentlatlen ot tbe aoute

tOxiolty arla.,

tpo.

almultaneous adminlatratlon of BPI and

Malath.lon, lnh1bltlOD of blood ObE . . . alao found to be more tbAn

ad41tlv..

No tata we.e obtalAed with reterenoe to the erteet ot

one of the purpoae,

tbl. c.-binatlon on O.I.S. CbB.

o~

tbe

pre.ent studJ ... to •• tabll.n wheth•• or Dot lnb1bltlon ot braln
CbE 18 al.. pot.ntlate4.
Up to the p.....t

,1m.

1t va. .qgeeted tbat tbe poten-

tlatlon pb.nomeDOD of ObE lDhlbltloD produoed bJ oo.blned

admlnlstration of or,ano.pboaphorua antl.holln •• t ...a. oompounds
1. due to the lnblbltlon bJ one ooapoW'ld of the de'onrloa'lon
of tile otb.er (COOl: t I poatulate).

WI til .e8&r4 to the \wo ooapound

.tudled at ppe.ent, EPIJ and Malath.1on, Ooole (18) baa allow that

lD vitro BPI' lobibS'e Malatb10n d.to:&1tl.at1_ bJ tb. 11....
Tbe , ••• emt IJI,_.t10 atudJ ahows 1ft d.tall bow b.a1D

ObE 18 atteoted bJ the oOllblnatlon of tboa. two oompound., hov

their en.,.10 attect II lntluenced
and wnatbep

01'

bJ

tbeir 11vep metabolla.,

Dot the ettect u.pon bFain .nzJ1I8 can ba conelatH

with the tOxioltl of tn. combination.

The•• data w111 b. now

lweu-l ••4 and oerta1n pointa atre.a" to show that vb.11. _OllIe
89

90

ot the

~esults

supports Cook'. postulate others do not, accord-

ingly. an alternative h1Pothesis is pre.ented at the end ot this
di.ou•• ion.
i1.

Surv.l ot the 19 vitro .tudies of
1.

IPN

and Malathion.

Single addition.
In vitro studies showe. that EPN has weak anticholin-

e.terase action and that inoubation with liver homogenate and
DP. l.ad. to the conversion ot EPN into a potent inhibitor ot

ObB.

fbis suggestl that in vivo ElN., has to be metabolized,

probably in the liver, to,be ettective .. an antichollneatera.e
asent, and contir.s earlier results on activation ot EPN by it.
incubation with the liver (61).

Incubation ot ErN with liver

homogenate in absence ot DrN has shown no detbite incre.. e In
It, antioholinesterase actlon.

In vitro .tudl.. ot Malatbion ,howed that a relatively
rapid d.er.... rather than incre••• of anticholinester... ettect,
tollowed it' inoubation with the 11ver nomogenate.

Thi. agree.

with the data obta1ned by Cook (19) showing that 1n vitro
Malathion 1, inactivat.d with1n llalt hour ot incubatlon.
Parathion, EPN and man7 other organopho.phorus compounds on the
other band are Dot inactivated by the liver.

Malathion .....

to be inactlvated .imilarly whether or not DrN vas added to the
incubation medium.

Thi. indicat.s that d•• truction of Malathion

and activation of ErN are carri.d out by two difterent enzyme

i
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systems of the liver.
2.

Combined addition.
Combined non-incubated EPN and Malathion producea in

vitro inhibition ot brain ChE equivalent to the inhibition
predictable on the baais ot an additive action.

On the other

hand cambination ot ElN and Malathion incubated with liver
homogeDat. produce. potentiation ot their antioholinesterase
ette.ts.

Thi. agrees with the data of Bo.enberg (13) indicating

tbat in vitro EPN and Malathion combination
potentiate the
.,
inhibition ot rat brain ChE only atter these compounds were
incubated with liver.
).

Type

ot

interaction:

In vitro stUdies have shown also that the interaction
between ErN and Malathion with ebE are ot an irreverlible t1Pe.
Moreover, when brain samples trom animals treated in vivo with
EPN

were added to and homogenized together with, brain aamples

trom untreated animall, the enzrme ot the latter was not inhibite. • This indicate. that no tree phosphonate compounds were
pre.ent in the brain ot EPN treated anima18 and pre.umab1y not
in the extra cellular Ipacel of the tilsues.

However, tinal

proot ot thia latter point depends on the use ot ditterent other
techni.u.. •
Tbis .et ot data Ihowa that the manometric ••thod can be
reliably u.ed to .easure the inhibition in vivo linea the latter
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could not be rever.ed in the course ot the preparation for
analysis nor could th. actual inhibition be increased by the rele.s. of the fr.. compounds during homogenization.

~he7

a180

show that there i8 at l ••st a cert.ain degr•• ot 8111ilaritl

..

between EPI and Malathion both being irreversible inhibitors
of ChE.
III.

Survez of the in v1vo studies ot the two compound.,
Systematic inv•• tigations have b.en carried out with

regard to EPI and Malathion administered by various rout.s Singly
or in combination to 4ne.thetl.ed animals.
1.

Sins,. a4!llJ1ltraticm'
a.

Eioch~1.a1

and toxic ette.t. of .ingle admini-

stration and relationship to toxicity.

On I.V. admini.tration

EPN was found to be & fa1rly potent antleholine.teraae agent.
significant brain anz,.. inhibition begins with a do•• of about
2 to 3 mg/.lg.

Oholinergic SJMPtoms develop.d and its s.verity

vas parallel to the cloaage glven.

Death dld not oocur until

about 90 percent lnntb1tlon ot normal activity of brain AcObE
1)

Val

reoorded.

On the othep hand Malathion given I.V. to anesthetIzed
dogs vaa found to b. a rather veak brain anticholine.terase
1)

It Wal notic.d that EPN, S mg/Ig given I.V. to atropinIzed dogl
d14 not produce bra1n OnE inhibition while it did 10 in nonatropini.ed doge (riye animal. were used in each ca.e). Thi.
might have a bearing on similarity between the enzyme and the
central receptor sites surtaces.
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agent, tnhibition began with a dose ot about 50 to 60 .g/Ig.

The

lethal d08e ot Malathion agreed tairly w.ll with that which
produced toxicity of non-an.sth.tized dogs , and was tound to be
about 400 mg/Kg.

The severity ot cholinergio 8Jmptoma were a180

papall.l to th. d08age giv.n, however, brain AcCnE inhihition at
toxic level was about 60 to 70 percent, i.e. le88 than the
inhibition produo.d br toxic d08 •• ot ElK.

The level ot inhibl-

tion ot about 90 p.roent characterlstic tor the lethal d08.. ot
!PH is in 010•• agr ••••nt with the relults ot Metz (62) who
produced re.piratory tailure with TEP-P at 90 perc.nt inhibition
levels .t ••dull&r1

A.abE.

In ease ot TEPP as probably allo in

that ot BPI' death can be attributed m08tl1 to inhibition of brain
AcOhE or more .peoifically to that of medullary AcOnE whicb i.
higher than that ot the cortical enz,..e.

on the other hand CbE

inhibition by Malathion was lower at deatb thaD that which
obtained not on11 with lethal doses ot !PN but also wi,h l.thal
dose. ot .everal other organopho.phorus compound..

Malathion

toxicit1 .e... theretor. to b. due to a combination ot brain
enzyme inhibition and other faotors.

The taotors that m«1 be

involved are as followa.
i.

Peripheral CbE

inhibition~

At 10 peroent inhibi-

tion ot C••• S. CbE the enzyme ot the li.M.J. and ot the ganglia
may be compl.tlr Inhibited; in tact, tn the cue ot Malathion
blood CbE ls coapletly inhibited when C.NeS. enzrme is only 70
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percent inhiblted, while wlth EPN central and peripheral chollnelterase inhibltion mal run parallel.

The importance of this

taetor cannot be aleertained, since the activlty of ChE in the
tis3ues

peripheral- other than in the blood- hal not been determlned in
the present Inve,tigation.
11.

Non-cnolin.,teraaic tactors lueh as dlreet

neuronal tOxicity central or perlpheral or both.

Actually,

central toxic6tl of Malathlon mal depend on a conditlon of direct
neuronal tOxicltl and of central CbE inhibltlon •
.,

In tact, the data obtained wlth regard to Malathion toxicltl mlght agree wlth Frawley data (33) indicatlng that In
the caae of certain organopho,phonate. convulalve do ••• produe.
relatlvell 11ttle central ensymlc inhlbition.

~h.

alertlng

ettecta ot ElK and Malathion upon the cat BEG as well aa thelr
antagoniam of atroplne ERG, studled in thla laboratory (7) are
ot inter.at in thil context.

The ettectlve doae ia 8 mg/Xg and

250 ms/Kg tor EPN and Malathion reap.cti••ly (7), actuallt
alertlng lometim.. could not be obtained with &Dl dose of Malathion.

Tbi. i. in agree.ent wlth the tact that the lethal dOle of

Malathion dld not inhibit brain AeOnE abo•• 70 percent level.
Thi. may allo lugge.t that of the two pOI.ib111tle. mentioned
above ot 8ither central non-eholinesteraale faetora or of
peripheral probabll cholin.aterasie factors as

cODt~lbuting

at

Malathion toxicity the latter ahould be consldered partlcularly.

9S
b.

Role ot metaboli.m.

Metaboli.m ot BPI and Malathion

artecta their antloholine.terase aot!vit!e..

Thi. was shown by

the difterence in potency ot their In vitro and in vivo anticholine.ter.. e action..

EPB vas a weak Inhlbltor in vitro

(Iso

= 2.>< 10-~) but a potent inhlbitor in vlvo, vhile Malathion was
tairly potent inhlbitor in vitro (I.$O
w.ak Inhibltor in vivo.

= 0.8x lO-.5M)

and rather

The ettect ot metabolism is also indi-

cated by the ditterenoe betw.en antlcnolinestera.e potency ot
the non-incubated and ot 11ver-incubate. compounds admini.tered
to the "upper animal· intrajugularly!or intraventricularl,..

In

thi. o.. e EPli, 10 JIg/Kg, did not attect brain ObE when admini.tered via either POute witnout previous incubation, while it cau.ed

signitioant Inhibitlon when given by either route atter liverinoubation, 1I0reover wnen thi. do.e ot EPN (10 Ills/Kg) is administered I.V. to the normal animal and thus metabolised (activated)
In vivo 90 peroent inhlbltion ot brain AeOnE r.sults.
Non-incubated Malathion adminlstered intrajugularly
to the "upper anbal· aigniticantly inhiblted brain ObE at the
doa.. of 2.$ to So mg/Eg, and only by halt as muoh after inoubation with 11ver homogenate.

The same do ••• wnen glven I.V. to the

normal an •• thetized anlmal inhibited ObE very slightly.
e.

Ditterential aftinltie..

Inter.stingly enougn,

Malathion and ErN ••e.ed to exhlblt dltterentlal aftinitle. to
varlous are.. ot the brain.

Independently ot tne route ot admini-
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.tration EPN always inhibited the medullary more than the

co~ic-

al enzyme, Malathion on tne otner band sbowed more atfinity to
oortioal than to medullary enzyme wnen adminietered to the normal
a

animal or 1ntrjugularly rothe "upper animal".
Malathion vae &'-inietaraa intraventricularl"

However, when
it inhibited the

medullvy enzyme more than the oortioal one.
Compounds admini.tered I.V. are generally expected
to

na•• more &c,o •• s to medulla tban to OOl't_. Ttle explanation

tor this being as tollowa.

The tvo onorlo1d plexl in tbe brain

enolo•• the torth ventricle

010 •• to~me4ull&l"1

lateral

v.nt~cl ••

area and the

in the neighborhood ot the cortex (Fig. lS).

As Inter.t1tlal fluld. and oompounds oapabl. ot orosslng bloodbrain barrier- pa•• t%l'om the blood to brain ventriol •• through
the ohriold plexl and a. the tluld In the lateral v80trlol.. 1,

conv8J" down to the tour-th ventricle, the IIMu11. should have
the chanee of abaorbing oOlllpound. both. trOll the chorioid plexu.a
1n its vio!n!t,. and trOll the tluld dueending UPOll it trOll the

lat.ral ventriolea.

On the other han. on intraventricular

admlnlats-atlon into the 1a,...1 ventr101.. the oortex would be
the near •• t to the depot ot the drug and more likely to be
attected by their actloas.

Obvlou81,. th••• topographical factor.

did not oontro1 the di.trlbut1on or EPN and l(alathion alnoe the
medulla vas the 81 te ot EPN aetion uPOD lntraventl'loular adminlstratlon whlle oortex Was mOltly afrected when Malathion was
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given I.V.
d.

Other factors must be involved.
Dual action ot !PH.

Anotner interesting observation

was that EPN had two actions upon brain OnE depending on ita
dose.

In

do.e. . . amall aa 1 to 2 m£/Xs given I.V. to tne

normal ane.thetized animal or given via the jugular or the
ventricular route to the "upper animal" EPN .ignificantly !ncreased its activity.

When EPH vas given I.V. in thea. do.e.

to normal anesthetized animal the increase in activity ot brain
ebE reaohed a maximum at

40 minutes and was followed by return to

control level or by slight inhibition.

Malathion on the other

hand did not inorease the activity of brain .nsrme at any .ubinhibitory dose level tried (10 to 100 mg/Xg).
e.

Effect on brain pseudo ChE.

The action of EPN and

Malathion tovards brain pleudo CbE should be also mentioned.

It

haa been found that their aotion on pseudo CbE vaa parallel to
that on AeOhE.

In the oas. ot EPN both activation and inhibItion

occured in parallel with regard to true and to pseudo brain ChE.
It is to be borne in mind that

~he

amount ot p.eudo OhE pre.ent

in the braIn is small and that thererore its inhIbition might be
expeoted not to be of great importance.

However De.medt (22)

claimed that toxicity ot organophosphorus oompounds is due to
inhibition of pseudo OhE rather than to that of AcOhE.

Thi.

conclusion can be criticized because most of the compounds ueed
by Deemedt could only poorelf penetrate through blood-brain
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bar~l.r

(Rol.atedt, 43).
t.

Role ot C.N.!. barrier.

Non-incubated EPN, 10 mg/Kg

did not produce any .ttect on bpaln AcChE when given Yia the
ventricular pout. to the "uppep animal".

At 20 mg/Kg. non-incu-

bated F.PN produced sOl'IIe inhibition ot tile anz,... when given intpajugularl, to the "upper animal".

This lndicate. that blood-brain

barrier dld not prevent the non-incubated (not actlYated) !PH
from reaching the brain, and that the Inhibitlon obtainea upon

I.V. adalnlatl'atlon was that which could b. expected on tne buia

ot quantltatlve penetration ot non-lncubated EPN into the brain.

It se... than that whl1e metabolla. ot EPN Inol'e...o It. InhlbltOPJ potanc7 ainee at a do.. ot level ot 10 mslRs only the
Incubated compound inhibited brain ebE regard Ie.. ot the pout.
u.ed, activation waa not required top making It absorbable via
tbe blood-bnln b8l'l'1er.

or
eDara.

Inotnet" worda lIetabolia.

Inor..... Ita capability ot attacking the brain

EPN
at the

cell alte.
Non-inoubated Malathion inhiblted brain ChE vbetbel'
admlnlatered via the jugular veln or Into the
"upper anllUl. It.

vent~lcle

or

the

Thia .howa a.1lo that Malatb.Iem penetration to

the ventriole Ie not oontpoled bJ the blood-bra1n bar:t-ler.

The

reductIon In 1nh.lbltlon was eimllar when liver-incubated Malathion was admlnlatered via .1ther route.

Thia indicat.a tbat

metabolla. do•• not alter Malathion penetra_l11ty through the
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blood-brain barrier.
2.

Oombined administration
•
•
a.

Eftects due to EPN given 30 minutes prior to Malathia

While inhibition ot brain OnE atter EPN-Malathion combination
vas Independently ot the dose. ot the two compounds always much
higher than the inhibitIon Which would result from additive
ettect ot both compounds. certain other results ot the combined
administration to anesthetized dogs depend on the dosage ot the
two components ot the combination.

When the doaes ot EPN and ot

Malathion were 2 and 10 mg/Kg respectively 8S percent ot animals
dIed.

Death occured within 10 mInutes and InhIbItion ot brain

ObE va. greater in the medulla (BS percent) than in the cortez.
On the other hand, when EPK and Malathion doses were 1 and So
mg/Kg respectively d••th occurea within

40 minute. and cortical

enz,..e va. inhibited more than the medullary enzyme.

'fb.1.

indicates that larger the ElN traction in the combined ao.inistration the taster death occured and the more inhibited va.
medullary ebE.

To the contrary, when EPN dose was lowered and

Malathion dose increased death occured slowly and the cortical
enzyme was inhibited more than the medullary one.

Thul as either

Malathion or EPN content ot the combination is increased,
inhibition at the site characteristio tor the pertinent compound
i. tound to predominate.

Thua in the case ot 2 and 10 mg/Kg

EPN-Malathion oombination medullary enzyme was inhibited by 8S
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percent wb11e in the ease ot 1 and So ms/Kg combination the
inhibition was only

SO

percent yet .eath occure. in both .erie••

Thi. again 1. another evidence indicating that Malathion toxicity
1. not entirely due to brain CbE inhibition.

The data maJ a18.

suggest tbat Malathion even when admini.tered ,30 minute. atter
EPN .eem. to prevent EPN from exerting its full actlon at the
medullary slte.
1.

Role ot metaboliam.

In the "upper animal"

combined Intrajugular or intraventricular administration ot noninoubate. EPN and Malathion produced:atter a characteristic
.elay (60 minute. atter the administration ot the .econd compound
potentiation ot the brain ObE inhibition.

Potentiation ot

inhibition vaa particularly pronounced in the cortex.

When the.e

compound. were similarly admini.tered atter inoubation with liver
homogenate potentlation ot brain CbE inhibition was produced
taster <at ,30 minutes atter the adminlstration ot the .econd
compound), to a greater extent, and It occurea in the cortex an.
in the medulla.

Again, the inhibitory etrect was potentlativ.

rather than additive.
li.

Role ot O.N.S. barrier.

When EPN, Malathion or

0-

their combinatioDS upon Intr.!entricule administration do not
inhiblt at certain dose levels unle.. incubated, this naturally
.eans that the metabolism ia nec •• sary tor aotivation and increaae ot inhibltory action aince blood-brain barrier doe. not

j
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matter in the ea.. of this route) on the other band, lack of CbE

inhibition upon intrajugular administration unle.s incubated of
single compound. or ot their combination. may mean that

1ncubatio~

ie needed both tor activation and penetration acro.. the bloodbrain baprier.
The pre.ent data obtained from combined adminiItration of EPN and Malathion indicate that .etabolism is oece.lary for taater and for more pronounced inhibitory potentiation.
Combination ot liver-incubate. compounds produ.ed potentlation ot
brain ebE inhibition in both cort.x and

~e.ulla,

at 30 minut ••

atter the administration ot the ••cond compound, while with nonincubat.d compound. potentiation of the enzyme inhibition ari ••s
to a l ••••r extent and not until 60 minut.s att.r Malathion
administration, thi. latter potentiation occur.. only in the
cortex.

Similar degree of potentiation occured on intrajugular

and intraventricular administration to tbe "upper animal-.

~his

indioate. that blood-brain barrier doe. not affect the penetration
of thOle compounds into the brain.
iii.

aelationship to toxicity_

Sin.e metaboli ••

(activation) of ErN incre.sed tbe pot.ntiative and anticholinester... aotivity in the 0.N.8., the potenttation of toxicity
with regard to combined admini.tration of EPN and Malathion could
be at le.at partly related to brain AcOnE inhibition.

It high

enough the latter could oau.. death directly or bping about
secondary tactors auch as cardiovascular disturbance which in
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turn may oontribute to toxioity.

However peripheral CbE inhibi-

tion at sites such as N.M.J. are very likely to contribute to
the potentiation of toxicity arising on combined administration,
since such factors .eem to contribute to the toxicity of Malathlo!
whon given singly.
The bioohemical data obtained in the present
study agree with the pharmacological data,

In this laboratory

it has been shown that good antagonism of atropine EEG and
marked alerting as well al convulsive REG pattern relulted from
combined administration ot EPN, 2
12 mg/Xg (unpublished).

to~4

ms/Kg and Malathion, 8 to

In this cas. the neuropharmaoological

data could be correlated with the inhibition of brain CbE.

On

the other hand, pharmacologically the potentiation was not
confined to the C.N.S. and eould be ob.erved a180 at peripheral
neuroettectors such a. neuromyal junction and at the ganglia
(Karommar, Awad and Blaohut, unpublished).

Also aa mentioned

earlier the present data showed that in the case ot combinationa
with a relatively high content of Malath10n the extent ot central
CbE inhibition at toxic dos •• is rather low.

The above results

suggest that both peripheral and central sites may be involved
in bioohemical and pharmacological potentiation and also in the
potentiation of toxicity.

Also, direct neuronal toxicity cannot

be excluded.
b.

Effeeta arising from varying the sequenoe of EPN and
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Malathion administration.
tion

d.scribe~

The potentiation ot brain ChE inhibi-

above was obtained when EPN was administered

prior to Malathion.

The question then arises whether or not

potentiation ot OhE inhibition would also occur it the sequence
ot administration ot Malathion and EPN were reversed.

As will

be seen this has a bearing on the mechanism involved in potentiation •
Studies were carried out with Malathion, 10 mg/Kg
administered prior to or simultaneously with lPN, 2 mg/Kg •
.,

While CbE inhibition occurred there was no death nor potentiation
ot inhIbition, although distinct cholinergic aymptoms and toxici-

ty aroa8.

The medullary ChE inhibition arising trom the above

oombination leemed to be le.s than that produced by similar
doses ot EPN given singly, suggeating that Malathion prevents
tull anticholinesterase .ttect ot EPN trom being exerted.
Similar interpretation can be applied to the tact that when
Malathion was given 30 minutes atter EPN medullary CbE reached

8S percent level with 10 mglKg dos8 ot Malathion but va. only

50

percent when Malathion dose in thil combination waa increased

to So mglXg.
It should be remembered that the dos8 ot Malathion

ot 10 mglXg did not produce per ae inhibition ot brain enzyme
even when administered into the "upper animal" where it escape.
inactIvation by the liver.

Thua it cannot be concluded on the

105
bali. ot thl1 experim.nt that potentiation of inhibition cannot
aria. trom thi. particular admini.tration ••quence) that this
actually can be the ca... appear. trom the Icrutiny ot the
tollowing .xp.rim.ntl.
When Malathion. 50 mg/Rs. was giv.n prior to EPN, 10
mg/Kg, death occurred within halt hour and brain CnE inhibition
reached 80 and 100 p.roent lev.ll In the medulla and cortex
re.pecti.ely.

Actually only 80 percent inhibition ot the corti-

cal enzyme could b••xpected on the ba.il ot additi.e etteeta ot
Malathion and ot ltPN.

Similarly wheb Malathion, 60 .g,lKg,

W8.8

given $0 to 120 minute. prior to BPN, ) mg/Kg, death occurred
within 60 minute. and again .ome potentiation ot CbE inhibition
occurred amounting to an a.erage ot 2) to )0 perc.nt increa.e in
inhibition above the l.v.l. .xpected on the baai. ot addit1ve
ettectl.

Those re.ult. are in agr....nt with data obtalned in

this laboratory indicating that potentiation ot toxicity and ot
neuroettector action d.velops on actmlni.t.ring Malatbion prior
to EPN in non-an •• th.tlzed

dog.~

In the case ot the N.M.J.

potentiation ot the mUlcle re.ponse to indirect stimulation
developed in ane.thetized cat. when sUbettecti.e doae. ot Malathion were given 50 minute. prior to aubett.otive do ••s ot EPN
(Karozmar, Awad and Blachut, unpublished).
Ther. was a relatively good corr.lation between
toxicity &nct brain OnE inhibition when subeftective dose. ot EPN
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was administered prior to subetteotive doses ot Malathion.

On

reversing thls .equenoe ot administration potentiation ot the
enzrme wal not .s high In the medulla and did not exoeed 70 percent In either cortex or medulla, at the tl.e ot occurrence ot
death.

In this ease other non-choline.teraaic taotors and / or

peripheral cholinesterasio tactors could have contributed to the
toxicity_

Thus, when EPN is administered prior to Malathion

toxicity appears to be mainly due to potentiation ot central
enzymio inhibition, although partioularly in the oas. ot high
oontent ot Malathion in the combInation peripheral tactors may
have oontributed.

When on the other hand Malathion waa admini-

stered tirst, toxicity may be due to oentral potentiative ettect
and also to potentiation at peripheral site8.
ported by the tact that in oombination there

This oan be supWal

alwa78 complete

inhibition ot blood CbE (a peripheral 8ite) while thia was not
the oase with brain CbE.

We may assume in thia oontext that

Malathion oonoentrates and oontributes to potentiation preterentially at peripheral 8it.s.

Ceratin pharmaoological data support

thia suggestion (lArc ..ar, Avad and Blachut, unpublished).
Hewever, aa Indicated above, direct neuronal toxicity ot comblnation may al.o exi.t.
IV.

Meohanism ot potentiation:
1.

pi8orlbtion ot Cookts postulate {Malathionase slstem and
its inhibition bl

EPB~:
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In 1957 Frawley showed that oombined administration ot
EPK and Malathion produced potentiation ot ebE inh1bition ot RBC
as well as potentiation at toxioity ifi rat..

Accordingly, Cook

(19) hypothesized that the potentiation occurs due to the inhibition by one oompound ot detoxitication ot the other.

ae showed

that in vitro Malathion ia metabolized and inactivated very
rapidly by liver homogenate.

Cook et ale (19) showed also that

detoxitication wal due to hydrolysis ot one at the succinate e.te
groups ot Malathion.

The,. a.sumad theretore that the enzyme is

an eaterue and called it "Malathion..s.".

None ot man,. other

organophosphorul compounds such as EPN, Ohlorthion, Guthion,
Parathion etc. was markedly altered by the liver.

Cook et ale

(18, 19) ahowed also that phosphonate compound. auch as EPN have
'igniticant inhibitory ettect on the degradation ot Malathion
when added to the liver homogenate either simultaneoully with or
prior to the addition ot Malathion.

This was confirmed by

MUl'phy and Dubois (65) who sbowed tnat So percent ot rat 11ver
detoxifioation of the enzrme "Malathiona•• ", occurred with a
concentration ot 2.8 ~ 10-5 M ot EPN in vitro.

When. 1.5 ms/Kg

was administered to rats 1 nour prior to Malatnion. thia dos.,of

EPN brought about a reduction in the LD50 ot Malathion trom 1100
to 550 mg/Kg.(l)
2.

Cook's gypoth.sls and the pre.ent results:
The results ot the present studt partially support and
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(1) There is no evldence to prove that "Malathionase". the
liver enzJMe delcribed by Cook is not a cholinelterase. Cook
et ale argued aa tollows In tavor ot .pecific "Malathion...".
a. TO. very rapid alteration in vitro ot Malathion by the
liver ditterl trom that shown tor organophosphate pe.ticide.
generally_ When cholinesterase and some aliesterasea hydrolyse
the.e phosphat. e.ters, the enzJNea are in turn inactivated
or inhibited so,that one mole ot enzyme hydrolyzes only one
mole ot phosphate betore it become. inactive.
b. On the other hand, in the cas. ot enzymes such as DFPaae
and Tabunase one mole ot en.,.. hydrolyses a large number ot
moles ot the susceptible phosphate wIthout the enzyme being
inhibited during the procesi.
Cook Itated that "Malathionase" action doe. not appear t(
resemble the activity ot either ot these two enzyme.. It i.
however not clear how does Cook know that "Malathionase" i8 not
de.troyed while hydrolysing Malathioh and thus ditters trom the
ali •• tarales, in tact, there was no quantitative study showing
how many mol.1 ot Malathion are hydrolyzed by one mole ot the
enzyme. Neither is it proven that ~alathionale" behave. unlike
DFPaa ••

c. The enzyme attackl Malathion at the di.thyl succinate
8ubltituent pather than at a P:S or P=O linkage aa i. do•• by
cholineltera•• , DFPase, and Tabunase. Howevel' it is not known
whether or not cnolinest.ra•• cannot attack tbi8 very linkage.
Thua, it ma, be more in keeping with available data to state
at pre.ent that the liver enzyme capable of de.troying Malatbion
may be a cholinest.r.... In tact Cook s'Sgest.d that tho.e
pho.phonate compounds which inhibited ~alathioDa••• beoom.
more potent upon oxidation Which however increased also their
anticholinesterase actiona. Similar ettect ot oxidation on
the.e two antlenzymic activitie. or the organophosphorus
compound. lugS.. ts that we deal here actually with one aotivity
only, namely that ot a cbolineateraae. It is further po •• ible
that Malathion react. with and 1s hydrolyz.d by, this .nzyme
thul producing a reverlible type ot interaction, while EPN al
well aa otber organophosphorus oompounds react with but are not
hydrolysed by, thi. enzyme thus producing an irreversible type
ot tnteraction.
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partially contradict Cook's h1Poth.sis.
a.

Facts sURPortins Cook's hypothesisl
i.

Liver metabolism and Malathion.

The present

study has shown that Malathion in vitro is a tairly potent anticholine.t.ras8 ag.nt.
activity d.crea....

When incubated with liver homog.nate ita
A do •• ot Malathion which does not inhibit

brain CbE when given I.V. produc.s about 14 p.rc.nt inhibition
when given intrajugularly to the "upper animal".

Incubated

Malathion produce. le •• inhibition In the ·upper animal" than the
non-incubated compound.

Thua, a1ao In vivo Malathion i. metabo-

lized, probably in the liver, to a 1••• activ. compound.

Thia

agre •• with Cook'. data indicating that a liver .steras. detoxitie. Malathion.
ii.

Ettect. ot non-incubated compound. in vitro.

Combined treat.mnt ot brain homog.nate in vitro by non-incubated
EPN and Malathion cau.e. no potentiation but additive CbE inhibition.

Thi. again agrees with Cook"

postulate .ince 1t in.ioat ••

that in order tor potentiation to occur !PH hal to protect
Malathion trom de.truction.
iif.

Bttecta ot non-incubated compound. in vivo.

Combined administration to the ·upper animal" ot non-incubated

EPN and Malathion given intrajugu1arly and 1ntraventricularly did
not produce potentiation ot brain ObE inhibition at 30 minutes
atter the admini.tration ot the .econd compound (Malathion) which
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i8 the time at which combination
produced potentiation.

o~

the incubated compounds

Thi. Is an In vivo

con~ir.ation o~

Cook's

suggestion that metabollsm Is necessary In order tor potentiation
to develop.
iv.

Ettects ot changing the sequence ot

admini~tratio

When EPN va. administered I.V. prior to Malathion in normal
anesthetized anual potentiation or inhibition or brai.n CbE vas
produced by inerrective doses of both compounds.

The reversal

ot the sequence ot adm1ni.tration lessened the action.

This

agree. with Cook's po.tulate that EP-N by being administered
prior to Malathion can protect the latter trom detoxifioation by
the liver enzyme, thus cau8ing potentiation
b.

o~

Malathion action.

'act. vhich do not 8upport Cook's hypoth.sisl
i.

Pote.tiation by inoubated compounds.

In vitro

combination ot liver-incubated EPI and Malathion produced
potentiation of the inhibition of brain CbE.

Also in vivo,

administration to the ·upper animal" ot the liver-incubated
combination ot EPN and Malathion produced potentiation ot brain
CbE inhibition.

It m1ght appear at tirst glance that this

tavors Cook'. statement since potentiation ocourred only 1n the
pre.en.e ot liver and since EPN could prevent in these conditions
destruotion ot Malathion.

However this is not the necessary

o.. e becau•• :
A.

The concentration ot EPN added was selected
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10 (ct. also p. 33) that EPN inhibited liver enzrme on17 and
was not available to protect any further detoxitication of
Malathion.
B.

In the ease ot non-incubated EPN and Malathi-

on administered 1ntrajugularly to the "upper animal" potentiation

ot inhibition of brain ObE did not occur at 30 minutes

at~er

administration ot the second compound (Malathion) aa already
atated.

However, at 60 m1nutes potentiation did appear, particu-

larly in the cortex.

Apparently then potentiation can occur in

conditions in which Malathion

oanno~

be

metabolized~hus,the

protection by EPN i. not the only factor involved.
C.

Finally incubated EPN given intraventricu-

larly potentiates ChE inhibition by non-incubated Malathion.
In this cas. again conditions tor Malathion de.truction are not
preaent.
ii.

Further anallsis of the ettect of changing the

sequence ot administration.

When Malathion is given

40

or even

120 minutes prior to EPN potentiation of brain Obe inhibit10n
and toxicity did arise in the cas. of min1mal eftective dose. of
these two compounds.

Thus BPN .ee.s to potentiate Malathion

even when given atter 1t, thus not being in posit1on to protect
Malathion from destruction.

It should be atated her. that Cook's

postulate becomes a working hypothe.is only it we analogize
Malathion to A.h; 1n other words it we assume that Malathion i8
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juat about a8 rapidly metabolized aa Ach.

In thi. caa. it could

be ea8ily vi.ulaized how aimultaneous administration of EPN and
Malathion or particularly pretreatment with EPN may lead to
potentiation ot the eftects ot Malathion.

To the contrary even

it 60 minute. atter administration of Malathion a certain amount

ot it remaina intact and is protected by EPN trom further destruction it i. hard to visualize how this protection should render
Malathion effective at that time.
ili.

Finally two more taots not reported in this work

but available from other investigations aeem to oontradiot Oook's
hypothesis I
A.

Rosenberg hal shown that Ohlorthion and

Malathion are both hydrolyzed by the liver and that Ohlorthion i.
potentiated by EPN and also potentiates Malathion.

On the other

hand Oook (18) has reported that Chlorthion is not hydrolyzed by
the liver and that both !PN and Ohlorthion inhibit Malathion
detoxitication by the liver.

It this is true then Chlorthion

potentiation by EPN cannot be explained according to Oook's
hypoth.ala.

On the other hand, It we accept that Ohlorthlon 1.

hydrolyzed by the llver it la dlfficult to visualize how it can
potentiate Malathion by the mechaniSM suggested by Oook.
B.

Potentiation cannot always depend on the

interferenoe ot one compound with the detoxification of the other
,inee similar potentiation was reported in the ca.e of combinatio)

ot neostigmine and oxamide bis-quaternaries (55).
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Those compounds

are not hydrolyzed by the liver.

3.

New postulat,:
Since several taets seem to argue against Cook's hypo-

thesis and since particularly the question raised in o.ii (p. 111)
seems to exclude EPN protection ot Malathion as a major mechrulism
tor potentiation, another postulate is proposed.
a.

The basil tor the new hypothesi.:
Some in vitro as well as in vivo results indicate

that Malathion when given after,

prio~

to or simultaneously with

EPN can prevent full effect ot the latter to be exerted.

This

oould be due to Malathion reacting taster with the enzyme than
EPN.

It may be that once Malathion combines with the enzyme it

blocks EPN trom the site or interaction with the enzyme.

It the

enzyme has only one cationic site (which can be phosphorylated)
Malathion could compete tor it with EPN.

This does not .eem to

be the ease since less than additive inhibition occurs even when
Malathinn produces only partial inhibition thus assumedly permitting EPN to exert additional inhibition.

A

slmil~

ditticulty

in explaining interterence by one OnE inhibitor with the aotion
or another waS reoorded in the past.

Koppanyi and Karozmar

(54)

have shown that small doses ot physostigmine presumably caps.ble

ot limited inhibition of ChE prevented pharmacological actions
or DFP.

While it oan be readily understood (Koelle, 51) how
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~.latlv.17

large dose. or pbJa.atlgmtne can

p~.t.ct

CbB from DrP

by ra••r81blJ binding tn. ena,.., It oannot b. ..8117 .een why
CbE inhibited .81 bJ 10 p.rQant only, should not be tully Inhibi-

ted by .ultable dose. ot DFP.
On tbe othel' hand, bota potentiation and Mutual
competition oould ba expected it phoapbonate and .elat., oompound.
could act upon tbe en.,... 11'1 two dlft.rent v.,...

Actually EPN

aa' Malatbion 40 not re.et 14entlc.l1y wltb ObE tbougn tb., both
a ••• to be 1.r..... lbl. inblbltoft_

that CbE haa

110• •

It i • •ugs.. ted &000"11'1811

tban one oa'lonlc ·.It. ot actlon with r.S81"d

to ErN and Mal.thlon_

Thl. poatulate could explain alao blockade

1.0 oer-taln coa41tl0•• of EPN b,. Malathion, .11'10. on• •1te could

be attaoked bJ MalatbloG wbil. the othe. could be attack.d bJ
EPN and blooked bJ MalatbioD.

Tbl. postUlate of .ultlpl. eat Ionic

81te. on ebE mole.ule ... ot 41ttePeatla1 60,1.1t10.

JIl attiDl-

'1.. ot '9'&1"1... utlobolu..tv.... at th... .1 t.. • • ., obvlat.
the dlttlcultl 1n upl.a1nlng botb potentlatlon

aDa tn,..t . . . ..

pnen_ena oocur1'1Dg w1th ._blnatloDa of antiebol1D ..t . . . .

as."

The p••1;u1at. 1. strengthened bJ tbe taO't ,bat aD'loholin •• t .....
action. of EPlf &Del Kalatb.1on 41tt. . in ••v.~al •••p.e'•• 8lD••
thi. aga1D Gan be explained l t CnE mol.cule hael .... than on.

oatlonic .1t.&
1.

Hal.tb.1cm cannot

ot bpa1D ebE wbll. EPN .an.

p~oduc.

100 pvcen' lnb.1bl tlon

IlS
li.

In vlvo Inhlbition by EPN is greater at medullary
The opposlte is true in the case ot

than at oortlcal levela.
Malathlon.
111.

EPN inhlbits RBO AcOnE more than it Inhiblt.

plasma ObE, again the opposlte ls true in the case ot Malathion.
lv.

Brain ObE inhibltion by EPN oorr.lates with the

toxiolty produced while Malathion s.ems to exhibIt elther
perlpheral or non-cholinesteraslc components ot toxic1ty.
v.

An Important ditterence ls that EPN was shown to

have a dual ette.t and can depending on the dOs"

activate or

Inaotlvat. brain ObE.
b.

Speoulatlve !!planation ot potegtla'ion on tq. basis

ot the new po,tulat.t
i.

Two typ.. ot EPN-ChE interactlon••

BPI is .etabolized preaumably in the liver in
two .tepa, fir.t to • oompound whioh incre •••• the activity ot
brain ObE.

Thi. can

oCO\U"

elther with regard to the Dumber ot

tree or aotive .nzJBle or with regard to the number ot active site
on the enzymio molecule.

The tormer may take plaoe by competing

with endogenous anticholine.terases (49), the latter may take
place by exposing active site8 on the ensJae surtace which are
normally hidden.
Second atep ot EPN metabolism brings about anoth.
compound which haa anticholinesteraae aotivity.
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ii.

Potentiation would then pesult when Malathion

having acoe •• to more active site. of the enzyme atter the ettect

ot EPN took place, would inhibit ObE more etticiently.

Given

alone, it would have difficulty getting to all lite., whioh i.
evidenced

by

the tact that Malathion i. unable to produce 100

percent inhibition ot brain ObE.

In tact, the actual inhibition

b,. EPN given .ingly may be greater than the apparent one .inee
the brain sample trom an EPN-tpeated animals i. compared to a
contpol sample the OnE ot which 18 not activated by EPN •
.,

111.

Occurpance ot toxicity.

It 18 .. sumed that the

bound enzyme 1. in eqallibpium with the tunctional enzJme and
act. as .torage trom which the latter can be peplenilhed.

In

combination, EPN and Malathion will tre. and expo•• the bouad
enzyme and inhibit it when it 18 in the unbound torm, thua,
nothing ot the stored enzyme would be lett available to replace
the functional enzyme when it gets inactivat,.;d.

When both the

atored and the functional enzymes are inhlblted, Ach would
accumulate and produces death, pre.umably via central eftecta
such as convulsion and respiratory failure.
iv.

Occurrence of toxicity atter the ohange ot

sequenoe of administration.

When Malathion i8 given prior to

EPN, some of it geta attaohed to the brain enzyme and at the
periphery.

This traction ot Malathion is unable to inhibit

until EPN activates the enzyme.

At that time potentiation of
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inhibition ot ChE would be a result of more etficient ettect ot
EPN and Malathion.

In this particular sequence or

adminis~ration

toxicity occurs rather slowly, while Malathion can exert ita
action immediately, EPN metaboliaM and activation takes time, and
the enzymic and pharmacologic etrect is thus delayed.

On the

other hand, when the administration aequence is reversed, Malathion ia administered at the time ot activation ot OhE by EPH,
in this ease toxicity ocours taster than in the tormer.

All this

doea not neoessarily imply that proteotion ot Malathion by EPH
trom the liver detoxifying enzyme ii not one of the mechanism
contributing to potentiation; in taot it is telt that the
.echaniam postulated by Cook as well aa that sugge.ted at present
mal be both operative.

Finally, peripheral oholinesterasio as

well as peripheral and oentral non-oholinesteraa1c tactors oannot
be excluded at present.

CHAPTER V

I.

P9£Poae ot thia atudl'
In 1957 Frawley et ale have ahown that combined adminis-

tration ot organophosphorus compounds, EPN and Malathion,
produced potentiation ot toxicity and ot inhibition ot RBC CbE
in rats.

Cook et ale (19) postulated that potentiation is due

to 1nhibition ot detoxltication ot one
compound by the other •
.,
They demonstrated that in vitro Malathion 1s de.troyed by the
liver and that EPN protects Malathion trom this destruction.
'1'hls waa contirmed by data ot Murphy and Dubois (6$). suggesting
that EPN inhibit. irreversibly the liver "Malathionaae".
Since death could not be attributed to inhibition ot CbE

ot RBCs and ainee no studies were carried out with regard to the
ettect ot organophosphorus combinations upon the brain enzyme,
detailed biochemical investigations ot brain CbE and ot its
interaction with EPN and Malathion and with their combinations
were undertaken.

Suitable daba were also collected tor re.x..i-

nation ot Cookla postulate.
II.

Progeaur!!1
1.

Ane.thetized dogs as well aa Ruppel" animal" preparations

were u.ed in the present study.
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In the ca.e ot the latter the
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agents could be

.'ministe~ed

so that they would not circulate in

the liver or any other visceral organs.

Both liver-incubated

and non-inoubated oompounds were adminlatered to the ·upper
animal" ao that the ettect ot metabolism on the oompounds in
question could be studied in vivo in abs.nce ot the animal'a own
"Malath.ionase".
2.

Intraventricular administration ot inoubated and ot non-

incubated compounds was used to study the role of their metabolism as well as of the blood-brain barrier in action of th.e
compounds and ot their combinations.:

3. A systematic study of EPN and of Malathion actions on
brain CbB was carried out in vl'ro as well

a8

in vivo.

In vivo,

dltterent parts ot brain tissue were analysed tor their CbE
activity.

4.

Warbupg manometrlc technique was used exolusively tor

measupementof AcOnE and BuChE actlvitl.s.

s.

Interaction ot EPN and ot Malathion with CbE was studied

using dialya18 and dilution techniques.

The compounda inh1bit

the enzyme irreversibly; also, no tree compounds could be de·
monstrated in tiasue samples trom animals treated in vivo •
Thus, no tree compound could be released during homogenization
and additionally inhibit the enzyme.

6.

Irreveraibility ot inhibition and abaence ot tree

oompounds atter their adminiatration indioat. reliabtltt, ot
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ot measurement. of ebE inhibition.
III.

aesult.:
1.

EPN vas found to be a weak ebB inhibltor in vitro. but

rather potent inhlbltor in vivo.

It has to be metabolized by the

liver to become an etteetive antieholinestera.e.
2.

In vivo, EPN inhibited medullary enzyme more than eorti-

oal one.

3. At toxio do.e ot EPN inhibited nearly 100 percent of
brain CbE activity.

4.

Malathion vas found to b.

t.~rly

active ant1cholinesteras

in vitro, in vivo It was weak inhibitor due to the taot that it
i. destroyed by liver enzrme.

S.

Malathion Inhibited cortical more tban ••4ull&rJ enaya••

At toxic dose It inhibited maximally only 70 percent ot brain
CbE) this .uggest. peripheral or non-cholinesterasi. oomponents

ot to%101t1.
6.

EPN was tound to have a dual ettect, 1n amall do.e. it

inore.. ed brain CbB actlvitYJ large d08es oaused inhlbltion, on
the other hand Malathion did not Incr ••• e the enzyme activity at
any do.e atudied.

7. EPN and Malathion Inhiblted

in

vivo brain p••udo ebE

aimilarly to the true CbE.

8.

Potentiation of enzymic Inhibition in vitro occurred

on11 from the eombination ot liver-incubated compound ••

9.
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Potentiation ot brain abE inhibition in vivo occurred

when EPN was given prior te Malathion.

When Malathion was given

prior to EPN, potentiation ocourred in the case ot certain doses
but it was less extensive than in the case ot the former sequence
10.

With both sequences ot administration death occurred.

The extent ot ObE inhibition ot ditterent parts ot the brain and
the speed with which toxicity occurred depended on the ratio ot
the two compounds in the combination.
11.

In the "upper animal" rapid and extensive potentiation

ot brain ObE inhibition occurred trom combination ot EPN and
Malathion when both compounds or EPN alone were incubated with
liver homogenate.

Some potentiation occurred however even in

the ca.e ot non-incubated compounds atter a prolonged delay.
12.

In the case ot intraventricular administration poten-

tiation occurred upon administration ot liver-incubated compounds.

13. Analysis and comparilon ot data obtained upon administration ot EPN and Malathion and their combinations intrajugularly and intraventricularly in the "upper animal" or I.V. in
the whole animal .ugge.t that liver incubation ot EPN activate.
the compound but is not necessary to enable it to cross the
blood-brain barrier; liver incubation ot Malathion inactivates it
but again does not attect its capacity to penetrate the bloodbrain barrier.
IV.

AnalIsis ot Cook's postUlate.

l~

Some ot the re.ult. obtained support Cook's hypothe.iaJ
some other do not.
1.

Potentiation ot toxioity and brain CnE inhibition

oocurs not only by administering EPN prior to Malathion but also
when this sequence is reversed.

Aocording to Cook's postulate

when EPN is admini.tered atter Malathion little or no Malathion
1. lett in the cas. ot Malathion-EPN aequence by the time ot EPN
administration and the protection ot Malathion re.idue by EPN
oould not result in potentiation.
.,

2.

Potentiation oocur. when incubated BPN i. adminis-

tered with Malathion intraventricularly or intrajugularly in the
"upper animal".

It is shown that EPN in the.e condition. does

not protect Malathion trom hydroly.is in it. inoubation medium.

3.

Other data as well as certain result. ot other

investigators also do not agree with Cook's po.tulate.

4.

A new postulate is based on the suggestion that

provided EPN and Malathion do not react identically upon ChE,
the potentiation may result trom their interaotion with the
enzyme and does not have to depend on the proteotion afforded
one oompound from destruction by the other.

Some ot the

difterenoes between ettect. ot EPN and Malathion are as tollows:

plasma CnE

a.

EPN but not Malathion has a dual action upon ChE.

b.

EPN inhibits preterentially RBC

and Malathion
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c.

EPN inhibits more medullary than cortical ChE;

the opposite is true for Malathion.
d.

EPN but not Malathion can produce 100 percent

inhibition of brain ChE at death.

5.

The new postulate suggests that.
a.

EPN is metabolized in two steps.

Metabolite 1

activates CnE; Metabolite 2 inhibits it.
b.

Activated ChE i8 more liable to inhibition than

c.

Malathion attaches itself to CbE but cannot

control ChE.
inhibit it efficiently until the aetivating action ot EPN takes
place, henee potentiation.
d.

Certain

o~her

aspects ot the new postulate and

their relation to data available in literature are analyzed
turther in the discussion.
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